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ABSTRACT
Unique to survival analysis of veterinary clinical data is classification of
observations from euthanized animals. The first study highlighted limitations of
Kaplan-Meier product limit analysis (KM) of veterinary clinical data. Three data sets
with different outcome proportions (alive, lost-to-follow-up, dead due to disease, dead
due to other, euthanized due to disease, euthanized due to other) were used. Different
classifications of observations from euthanized animals caused inconsistent
conclusions of significant differences between strata within data sets. At times,
ranking of median survival time estimates for strata was reversed. The KM was found
inappropriate to evaluate observations from euthanized animals. This finding, coupled
with restriction of KM to two-state description of disease (alive to outcome), prompted
exploration of an alternate analysis method.
Markov models allow modeling of multiple health states and outcomes. A 5state, time-homogeneous, Markov chain was used for a cohort of 64 dogs with
generalized lymphoma. The model contained two transient (WELL, TOXIC) and three
absorbing (DEAD, EUTHANASIA, LOST-TO-FOLLOWUP) states. The transition
probability matrix (P) was used to iterate future transitions and survival probabilities.
Matrix solution and Monte Carlo simulation were used to estimate survival time.
Estimates appeared reliable.
Markov modeling was extended for comparison of vaccine-associated sarcoma
progression after treatment in a cohort of 294 cats. For a 5-state model, transition
probabilities derived from exponential transformation of incidence rates were used to

xii

construct P for each treatment – NONE (no surgery), SX (surgery) and SX+RAD
(surgery and radiation). Monte Carlo estimates of durations in transient states and
expected survival showed SX+RAD prolonged expected survival significantly longer
than SX than NONE. Commitment to repeated treatment with surgery and radiation
did prolong expected survival of cats with vaccine-associated sarcoma.
Assumptions of Markov modeling did not appear prohibitive for analysis of
veterinary clinical data and further exploration is warranted.
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CHAPTER 1 INTRODUCTION/LITERATURE REVIEW

1

1.1 Introduction: Definition of the Clinical Epidemiology Problem
Veterinary studies investigating clinical disease are usually directed at testing
hypotheses of treatment protocols or identifying prognostic factors. The question of
interest is often whether the probability of success is greater with one treatment than
with the other, or with the presence of one characteristic versus another. Success for
most of these studies is survival. Survival is however, an unrestricted end point and
survival must be estimated indirectly from the occurrence of death. Thus, the outcome
of interest for these studies becomes death.
Scrutiny of the veterinary literature over the last 10 years shows investigators
almost exclusively use Kaplan-Meier product limit estimation for evaluation of timeevent data (Thompson and Fugent, 1992, Al-Sarraf, et al., 1996, Blackwood and
Dobson, 1996, Kuntz, et al., 1997, Levy, et al., 1997, Dunning, et al., 1998, Khanna, et
al., 1998). These methods are simple and make efficient use of truncated or censored
data (Hillis, et al., 1986). They are restricted by assumptions of non-informative
censoring and limit the description of disease to permanent transition from one state
(alive) to another (dead).
Many clinical studies involve complex changes other than death, for example,
relapse, recurrence, recovery, and remission. Investigators will force this complexity
to fit with Kaplan-Meier methods by evaluating time to recurrence or relapse (Hillis,
et al., 1986). This fragments the investigation and if explored out of context with other
outcomes, results in incomplete evaluation of the data.
Veterinary clinical studies pose a unique situation since many subjects in these
studies are euthanized. Veterinary studies include a high frequency of euthanized
2

subjects, sometimes over 50% of the total observations are from euthanized animals
(Cox, et al., 1991, Berg, et al., 1992, Munana and Luttgen, 1998, Zwahlen, et al.,
1998). While death remains the outcome of primary interest in such studies,
investigators are inconsistent in their attention to euthanasia. Investigators have
ignored, deleted, censored or simply equated with death any observation that
terminates in euthanasia (Al-Sarraf, et al., 1996, Kuntz, et al., 1997, Dunning, et al.,
1998, Khanna, et al., 1998). Other investigators acknowledged that euthanasia posed
an analytical problem (Slater, et al., 2001, Staatz, et al., 2002) but chose to ignore the
problem and equated euthanasia with death. One investigator considered it imposed
normal variation into analysis of veterinary studies (Slater, et al., 2001) while the other
proposed there was justification for exclusion of these observations but did not
substantiate this statement (Staatz, et al., 2002).
The decision to euthanize an animal is based on several factors that include the
health of the animal, age of the animal and cost of the treatment (Gobar, et al., 1998,
Mallery, et al., 1999). Thus, euthanasia should be identified as an outcome of
secondary interest. Euthanasia can be recognized as a censored observation since it
will cause some subjects to fail before they reach the outcome of interest (Lagakos,
1979).
Unfortunately, simply censoring the observations from euthanized animals is
not appropriate. Euthanasia may be unrelated to the disease of interest. However, in
most situations, the time of euthanasia offers some information on the time of death
and the observations are informative. Euthanasia also represents a competing risk
(Lagakos, 1979). The objective for most competing risks is to estimate the time of
3

failure from a particular cause when other causes of failure are not in effect. However,
for euthanasia, the complete observation of the survival time of interest is an
unachievable event (Lagakos, 1979).
Thus, two limitations of conventional survival analysis methods currently used
for investigation of veterinary clinical studies become apparent; 1) they are inadequate
to describe the complexity of disease beyond two simple states of alive or dead (or
some isolated intermediate endpoint), and 2) they are inadequate to handle the
complicated issue of observations from euthanized animals.
An alternate strategy to describe and evaluate time-event data is the use of
Markov models. A Markov model is a stochastic model (one which models random
events) used in diverse fields such as computer science, engineering, mathematics,
genetics, agriculture economics, education and biology (Hillis, et al., 1986, Jain, 1986,
Stewart, 1994). Markov models have been used to describe human disease processes,
for example, the evaluation and description of diabetic retinopathy (Marshall and
Jones, 1995), systemic lupus erythematosus (Silverstein, et al., 1988), renal disease
(Schaubel, et al., 1998), papilloma virus and human immunodeficiency virus
(Hendriks, et al., 1996).
Markov models can be used to describe disease as a series of probable
transitions between health states. This methodology has considerable appeal for use in
veterinary clinical studies since it offers a method to evaluate multiple health-states
simultaneously. In addition, it potentially offers a method to accommodate
observations from euthanized animals by recognizing euthanasia as a concurrent
outcome of interest.
4

Markov models of veterinary clinical disease have not been described. This
investigation highlighted the limitations of Kaplan-Meier product limit methods for
time-event data in veterinary clinical studies, explored the application of a Markov
model for a veterinary clinical data set and used a Markov model to describe and
estimate expected survival in a veterinary clinical cohort.
1.2 Markov Models Overview
Markov modeling is a form of stochastic modeling that describes a process as a
series of probable transitions between states. For example, the natural course of a
disease can be viewed for an individual subject as a sequence of certain states of
health (Beck and Pauker, 1983). A Markovian stochastic process is memory-less.
Knowledge of the current state is sufficient to predict what the future state will be and
is independent of where the process has been in the past. This characteristic is also
described as the (strong) Markov property (Norris, 1997).
The Markov process can be classified according to characteristics of the state
space being measured. A discrete or finite space is assumed for most purposes and
implies there is a finite number of states that will be reached by the process (Jensen
and Bard, 2002a). A continuous or infinite process is possible. The Markov process
is also classified according to the time intervals of observation of the process.
Processes may be observed at restricted or discrete intervals or can be observed
continuously (Kempthorne and Folks, 1971).
The term Markov chain is used to describe a process observed at discrete
intervals. A Markov process described a process observed continuously. Some
investigators prefer to describe Markov chains as a special case of a continuous time
5

Markov process, that is, the process is really a continuous-time Markov process, only
it is observed at discrete intervals (Marshall, 1990). The term Markov process can thus
be used to collectively describe all processes and chains.
Another important distinction of Markov processes is that of time
homogeneity. When the transition probabilities are constant regardless of the time of
observation, the process is time-independent or time homogenous (Beck and Pauker,
1983) and the distribution of the number of transitions into a state follows a
homogenous or stationary Poisson process. The Poisson distribution is described as
Pr{N (t ) = k} = (λ t k e − λt ) k ! where λ is the average number of transitions per period t
(or the rate of arrivals) over k cycles (Jensen and Bard, 2002b). The time between
transitions in a homogenous Poisson process follows an exponential distribution
defined by the same parameter λ (Meeker and Escobar, 1998a).
Time homogeneous Markov chains best describe short-term medical problems
in people. Time non-homogeneous models may better describe chronic disease in
people (tens of years) since other factors such as age influence the transition
probabilities and cause them to be time-dependent (Beck and Pauker, 1983). Markov
models can be generalized to observations made at regular time intervals, at irregular
time intervals, or where observations are made at irregular intervals but the exact time
of transition during that interval is not known (Marshall, 1990).
1.3 Discrete Time Markov Chain
Consider the time-homogenous model where the transition probabilities are
constant over time. The transition probability matrix P(t) contains the probabilities for
the transitions. Since the probabilities for the time-homogenous model are constant,
6

the probability matrix could simply be written as P (Figure 1-1). The rows represent
the current health state and the columns represent the future state. The probabilities are
described as pij where p is the probability of moving from state i to state j for any
given cycle.

1
P=
2

 3

1
p11
p21
p31

2
p12
p22
p32

3 
p13 
p23 

p33 

Figure 1-1 Probability transition matrix for a time homogeneous 3-state Markov
model.
The sum of the row probabilities equals one since each health state is
independent of the other and an animal must move to one of the three states. The
diagonals represent the probability of staying in the same health state. A state is
considered absorbing when the probability of leaving a state is zero. For example,
being dead is an absorbing state.
1.4 Continuous Time Markov Process
The transition between states is viewed as a rate for a continuous-time Markov
process. The transition rate does not depend on the length of the observation interval
since it is the number of transitions that occur per unit time. The transition intensity
(rate) matrix Q(t) contains components qij which are transition rates from state i to j.
Since the rates for a time-homogenous Markov process are constant, the rate matrix
could simply be written as Q (Figure 1-2).

7

1

1 q
11
Q=
 2 q21

 3 q31

2
q12
q22
q32

3 
1
2
3




q13  1 − ( q12 + q13 )
q12
q13

≈

q23   2
q21
q23
− ( q21 + q23 )
 

q33   3
q31
q32
−(q31 + q32 ) 

Figure 1-2 Transition intensity (rate) matrix for a time-homogenous 3-state Markov
model.
The rate of staying in state i, is constrained to equal the rate of leaving i
(Norris, 1997). This is imposed by the fundamental property of the Markov process
that dictates that flow in and out of the state must be equal. The exception is when the
state is absorbing such that the flow out of the state is zero. In this case 1 is imposed
on the diagonal (Norris, 1997).
The probability of transition in a Markov process depends on the transition rate
and the observation interval. The transition probabilities can be estimated from the
transition rates. Consider the time-homogenous model where the transition rates are
constant. The distribution of time between transitions follows a one-parameter
exponential distribution; in fact, the exponential distribution is the only distribution
that has the memory-less feature (Meerschaert, 1999b). The cumulative density
function of time is Fi (t ) = 1 − e − λit where λi is the rate of transition up to time t
(Meeker and Escobar, 1998a, Meeker and Escobar, 1998b). The cumulative
distribution function describes the probability of transition before time t and thus can
be used to derive the probability of transition from the rate of transition such that
p = 1 − e − λit where t is the time period for which the probability is estimated (Beck and
Pauker, 1983, Miller and Homan, 1994).
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In matrix notation, dP(t ) dt = P (t )Q . Since the process is stationary in the
time homogeneous model, P(t ) = P( s, s + t ) = P(0, t ) and P(t ) = exp(Qt ) (Kalbfleisch
and Lawless, 1985, Qin, et al., 1997). The calculation of the individual transition
probabilities for any given value of t requires the spectral decomposition of Q(t)
(Marshall, 1990, Norris, 1997).
1.5 Time Non-homogeneous Markov Process
Both discrete time and continuous time Markov processes may be time nonhomogeneous. The relationship between the transition rates and probabilities are more
complex and computing probabilities is difficult (Marshall, 1990). In a time nonhomogenous Markov process, the transition rate and the transition probability depend
on the time of observation of the process. Similar to time homogeneous Markov
processes, the transition probability depends on the observation interval but the
transition rate does not. Because of their complexity, time non-homogeneous Markov
process will not be addressed further in this work (Marshall, 1990).
1.6 Markovian Assumption
The Markovian assumption initially appears restrictive but is easily met in
most cases. Adding states to the model may be useful when situations possibly violate
the Markovian assumption (Hillis, et al., 1986, Sonnenberg and Beck, 1993, de Kruyk,
et al., 1998). For example, passage to the state of death may occur at a different rate
following first remission of a disease than second remission. Under the strategy of
adding states, entry into the first of these states forces movement into the following
state and there is no backward movement. These states are referred to as tunnel states
since they can only be visited in a fixed sequence (Sonnenberg and Beck, 1993).
9

Although addition of states may avoid violation of the Markovian assumption,
it will increase the complexity of the model and reduce the density of the data for
estimation of transition probabilities. At some point in model construction, there may
be limited gain from adding states in the face of loss of precision of estimation of the
transition probabilities.
1.7 Time Homogeneity and Models with Covariates
The assumption of time homogeneity simplifies the Markov model and is often
a convenient baseline for analysis (Kalbfleisch and Lawless, 1985). Insight can be
obtained by examination of departures from this model. Consideration of the
assumption of time homogeneity is however, warranted. Many covariates may be
responsible for causing the process to be non-homogenous over time. The most
common covariate in people is age. Time homogeneity is often violated in modeling
chronic disease in people since aging and development of concurrent illnesses have a
significant influence on mortality rate (Beck, et al., 1982). Whether aging significantly
influences mortality in veterinary studies is undetermined.
A strategy for accommodating non-homogenous transitions is to add states to
the model. The strategy comes at the cost of increased model complexity and
subsequent computations (de Kruyk, et al., 1998). Alternately, separate matrices using
the same model can be created and compared for different time periods (Urakabe, et
al., 1975, Sendi, et al., 1999b). For example, where age-dependent transition was
suspected, investigators stratified the model by age groups and created separate
transition matrices for different age groups (Schaubel, et al., 1998, Jacobs, et al., 2001,
Pokorski, 2001). The strategy of creating separate matrices can also be used to
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compared fixed covariates such as treatment and disease characteristics (Silverstein, et
al., 1988, Sendi, et al., 1999a, Jacobs, et al., 2001).
For some causes of time-dependent transitions, separate models may be
required for each time interval that run simultaneously (Kalbfleisch and Lawless,
1985). In Schaubel’s study on the progression of renal disease, transition was
dependent on age and whether or not the subjects had diabetes. Separate models were
created for age groups with or without diabetes (Schaubel, et al., 1998). In this case,
the models were separate and no information was transferred between models. In de
Kruyk’s study on aortic valve replacement, transitions were dependent on the time
since the previous valve replacement and the number of previous replacements (de
Kruyk, et al., 1998). The latter dependency possibly represents a Markovian
assumption violation. Separate models were created for different valve replacement
occurrences. The models were run simultaneous and there was some information
transfer between models. In Ward’s study on the effects of climatic variables on
Bluetongue virus infection in Australian cattle herds, two separate models were used
and the matrices were multiplied to determine the overall matrix of the model (Ward
and Carter, 1996a). The first matrix represented the risk of infection in various age
groups while the second matrix represented the transition of cattle from one agespecific class to the next. These matrices, multiplied by a distribution vector,
determined the distribution vector of the proportion of cattle infected with bluetongue
in each age class.
Another option for incorporating time-dependent covariates in the Markov
process is to build the covariates into the determination of the time-dependent
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transitions rates (Kay, 1986, Marshall, 1990, Wanek, et al., 1994, Marshall and Jones,
1995, Christodoulou and Taylor, 2001, Jacobs, et al., 2001). The transition rate

λij ( t , z(t ) ) at time t, is described by λij (t ) = λij (t )e

βij z l

where λij (t ) is the baseline

transition rate from state i to j at time t, βij is the vector of regression coefficients

[τ l ,τ l +1 ] and

z(t ) = z l is the vector of covariates constant for every t within [τ l ,τ l +1 ]

(Kay, 1986, Marshall, 1990). This technique is akin to regression on the hazard
function estimation (Marshall, 1990, Perez-Ocon, et al., 2001). Fixed covariates can
also be built into the determination of transition rates for the time-homogenous
process, assuming a constant baseline transition rate such that λijl = λij e

βij z l

where λij is

the baseline transition rate from state i to j, βij is the vector of regression coefficients
and z l is the vector of covariates (Marshall, 1990). Using the technique of regression,
many covariates can be incorporated such as population mortality (Beck, et al., 1982,
Beck and Pauker, 1983, Kuo, et al., 1999, Jacobs, et al., 2001), disease characteristics
(Marshall, et al., 1993, Wanek, et al., 1994), age (Christodoulou and Taylor, 2001) and
treatment (Perez-Ocon, et al., 2001).
1.8 Description of Disease
An attractive feature of Markov models is their ability to describe the course of
disease over time. This is especially attractive for modeling chronic disease since a
subject’s state of health during the course of disease influences medical decisions. The
transition probability matrix P summarizes the probabilities of events and can be used
to depict the probabilistic course of the disease for a population or for an individual
with a known health state.
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Matrix multiplication estimates the probability of reaching a certain state for an
average subject after n cycles. In addition, matrix multiplication estimates the
proportion of a population that reside in a certain state after n cycles. The elements of
the probability matrix pij describe the probability of going from state i to state j in one
cycle. The operation P ⋅ P ⋅ P ⋅ ⋅ ⋅ P (n times), depicted as P(n) = P n yields a matrix
denoted the nth matrix, whose individual elements pij(n) are the probabilities of
transition to state j from state i after n cycles (Stewart, 1994). This information is
pertinent to a population as a whole rather than the individual.
A transient analysis is used to predict future health states for an individual
subject, conditional on their current health state (Jain, 1986). Consider the probability
of being in any one of a comprehensive and mutually exclusive assembly of m states
at a given time t, denoted by the vector p(t ) = [ p0 (t ) p1 (t ) p2 (t ) ⋅⋅⋅ pm −1 (t )] where
pi (t ) is the probability of being in health state i at time t. The probability of moving
from state i to j is given by the ijth element of the P matrix, thus the probability of
being in state j at time t is given by the jth element of the vector p(t + 1) such that
p(t + 1) = p(t ) ⋅ P . Iteration for further time sequences generates a series of
probabilities over many cycles (Urakabe, et al., 1975, Beck and Pauker, 1983,
Silverstein, et al., 1988, Bauerle, et al., 2000). The transient analysis provides
prognostic information suitable for individual decision-making (Urakabe, et al., 1975,
Silverstein, et al., 1988). Graphic depiction of these transient probabilities produces a
probability curve, which is illuminating (Urakabe, et al., 1975, Silverstein, et al., 1988,
de Kruyk, 1998 #149, Kuo, et al., 1999, Bauerle, et al., 2000, Myers, et al., 2000). The

13

probability curve is sometimes referred to as a “Markov survival curve”, in the case of
a model with absorbing states (Sendi, et al., 1999b).
Transient analysis may cause convergence of the probability distribution vector
to tend to a limiting specific value as n increases. That is, as the number of cycles, n,
increases, the probability vector approaches a limiting value. This is the concept of
steady state. Not every Markov chain possesses a steady state. The steady state vector
can be solved using the equation π = π ⋅ P where π is the steady state vector for m
states that contains the steady state probabilities π 0 , π 1 , π 2 ,....π m-1 under the constraint
that

∑π

i

= 1 (Meerschaert, 1999b). When a model contains absorbing states that

communicate directly or indirectly with all transient states, the state distribution vector
will converge so that the probability of being in a transient state as zero.
1.9 Model Validation
The two most fundamental assumptions commonly underlying a Markov
model are the Markovian assumption and time homogeneity (Garg, et al., 1990,
Marshall, et al., 1993, Hendriks, et al., 1996, Sendi, et al., 1999a). Assessing the
model to determine if these assumptions hold may take several forms.
At its simplest, the hypothesis of time homogeneity for a discrete Markov
chain is tested by the likelihood ratio test (Jain, 1986). This test compares the observed
transition probabilities with expected probabilities derived from the model
(Kalbfleisch and Lawless, 1985).
Data splitting (Lawless and Yan, 1993, Schaubel, et al., 1998) and sensitivity
analysis can be used to critique the model (Lawless and Yan, 1993, Cowen, et al.,
1994, Sendi, et al., 1999b, Aoki, et al., 2000, Jacobs, et al., 2001). These methods do
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not specifically test the assumptions but reveal inconsistencies in the model.
Inconsistencies may reflect violation of assumptions or other problems such as
imprecise estimates or flawed data.
Data splitting is separating the data set and using one portion to fit the model.
The model is used to predict the expected state distribution for a future time period
that are compared to the observed state distribution of the remaining data already
collected (Lawless and Yan, 1993, Schaubel, et al., 1998). If the data is dense enough,
separate models may be fitted for several different time intervals and compared
(Kalbfleisch and Lawless, 1985). This provides a method of internal validation of the
model (Schaubel, et al., 1998, Sendi, et al., 1999b).
Sensitivity analysis provides a tool for studying the behavior of the model
(Sendi, et al., 1999b, Aoki, et al., 2000). It does not provide any confidence statements
about the results. One-way sensitivity analysis provides an incomplete estimation of
uncertainly because the results are a function of the entire matrix and not just a single
probability. Assessing overall uncertainty should be done by statistical approaches
such as bootstrapping or Bayesian methods (Carpenter, 1988, Craig, et al., 1999, Craig
and Sendi, 2001).
Sensitivity analysis puts the probability of variables in the model through a
range of possible (plausible) values (0 to 1) and the outcome of the model is
examined. Traditional one-way sensitivity analysis examines one variable at a time
(Aoki, et al., 2000). Manipulation of two or more variables together becomes complex
because a two or more dimensional polyhedron rather than a single line describes the
range of values (Jensen and Bard, 2002b).
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The predictive validity of a model can be tested by comparing predicted
intermediate or final outcomes with observed outcomes of a separately cohort (Sendi,
et al., 1999b). An independent data source suitable for comparison may be difficult to
find and data splitting can be used as an alternative measure (Lawless and Yan, 1993,
Schaubel, et al., 1998, Sendi, et al., 1999b).
Face validity defined by Sendi describes how closely what happens in the
model compares to what should be happening, using different starting conditions and
medical interventions (Sendi, et al., 1999b). Sensitivity analysis provides some
insight into face validity of a model. However, additional scrutiny by visual inspection
is helpful. Comparison of the “Markov survival curves” generated by transient
analysis from sensitivity analysis reveal if changes to the model give unexpected
results.
1.10 Linking Markov Models to Survival Analysis
Although the Markov model is presented here as an alternate for survival
analysis, the methodologies used for survival analysis and Markov models can be
linked.
The Kaplan-Meier product limit model (of survival analysis) is a simple
stochastic process that is defined by a set of transition matrices (one for each followup time interval) that contain probabilities of transition from state ALIVE to state
DEAD (Hillis, et al., 1986). The transition matrix over the cycle t to t+1 has the
following form (Figure 1-3). This would reduce to P for the time homogenous model,
which would be assumed in the Kaplan-Meier analogy.
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Pt ,t +1


=  ALIVE
 DEAD

ALIVE DEAD 
pt ,t +1 1 − pt ,t +1 
0
1 

Figure 1-3 Probability matrix for a two-state Markov model of survival.
Thus, pt, t+1 is the probability of staying alive over the cycle t to t+1. If the
Markov process is applied to derive the estimated probabilities of moving from
ALIVE to DEAD at each time period, this calculation would equal the Kaplan-Meier
product limit estimate of the survival function, given 100% complete observations
(Hillis, et al., 1986, Marshall, 1990).
The corresponding transition rate matrix has the following form where the rate
of dying over the cycle t to t+1 is described as λt ,t +1 (Figure 1-4). Again, this would
reduce to Q for the time-homogenous model.

Qt ,t +1


=  ALIVE
 DEAD

ALIVE
−λt ,t +1
0

DEAD 
λt ,t +1 
1 

Figure 1-4 Transition intensity matrix for a two-state Markov model of survival.
The probability transition matrix is derived by spectral decomposition of Q,
remembering the exponential distribution of time (Figure 1-5) (Marshall, 1990).

1 1 e − λt
P(t ) = 

0 1  0

0 1 − 1 e − λt 1 − e − λt 


=
1  0 1   0
1 

Figure 1-5 Spectral decomposition of the probability transition matrix Q.
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Thus, the probability of being alive at time t is pt = e − λt . This is equivalent to
the exponential survival function S (t ) = e − λt (Hillis, et al., 1986, Marshall, 1990).
1.11 Censoring and Multiple Outcomes
A proportion of subjects in a clinical study are sometimes removed or lost from
the study before the outcome of interest is recorded. There are many reasons for this
including completion of the study, patient or owner decisions to remove themselves
from the study, development of other problems that prohibit completion of the study
and death due to other causes. These observations are considered right-censored
observations (Lagakos, 1979).
A powerful feature of survival analysis is the ability to use information from
right-censored observations. The underlying assumption for using these observations
to estimate parameters is that the censored observations are not informative. That is,
they do not provide any information regarding the time at which the outcome of
interest occurs. If the observations are clearly noninformative, then standard survival
analysis methods can be employed (Lagakos, 1979). It is not always apparent that
censoring is noninformative however, it is often clear that censoring is related to the
ultimate survival time. The most common forms of informative censoring are 1)
where subjects (or owners of pets) remove themselves from the study for reasons
possibly related to treatment; 2) where subjects experience a specific critical event
such as metastasis that prohibits them from continuing in the study; and 3) where the
subjects fail due to a secondary outcome of interest that causes them to be censored
according to the primary outcome of interest (Lagakos, 1979). This third scenario also
represents the presence of a competing risk. It is often easiest to view competing risks
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as a censoring problem. The third scenario becomes complicated because the objective
for most competing risks is to estimate the time of failure from a particular cause when
other causes of failure are not in effect. However, in this case, the complete
observation of the survival time of interest is an unachievable event (Lagakos, 1979).
Euthanasia fits this scenario.
Censoring can be accommodated in Markov models under the same
assumption of noninformation (Hillis, et al., 1986, Marshall, 1990). Subjects only
contribute to the risk set for as long as they are observed and do not contribute to
calculations of transition from state they are in when they are censored (Olschewski
and Schumacher, 1990, Marshall and Jones, 1995). In a simple two-state model, rightcensoring can be linked to conventional survival analysis as before. Using the
exponential survival function, the contribution of a censored observation is the
survival function S (t ) = e − λt (Lee, 1992b). Similarly, for the time homogenous twostate Markov model, the contribution of a right-censored observation is equivalent to
still being in the ALIVE state at the end of the study and therefore the contribution
over cycle t to t+1 is pt ,t +1 = e − λt (Figure 1-5).
The use of a Markov model for right-censored data has an advantage over
survival analysis in that each censored subject contributes more information to the
model than it can contribute to survival analysis with one end point (that the subject
did not reach). The prior state transitions these subjects experience add useful
information (Hillis, et al., 1986).
Creation of separate absorbing states may be indicated when there is
informative censoring or competing risks (Hillis, et al., 1986, Diggle and Kenward,
19

1994). Markov models allow joint analysis of competing risks by including several
absorbing states (Chevret, et al., 2000). The Markov model is particularly suited for
the scenario where subjects are removed from the study because they develop a critical
event that precludes them from developing the outcome of interest, for example
metastasis (Lagakos, 1979). The Markov model can integrate this information into the
description of the disease. Also, including the subject avoids loss of information on
prior transitions.
Survival analysis becomes unreliable when a large proportion of the data is
censored, since the estimates for the tail of the survival function are based on fewer
and fewer subjects (Hillis, et al., 1986, Lee, 1992a). Intuitively, this would also affect
estimation from the Markov model since transition probabilities to absorption states in
latter cycles would be based on few observations. The effect of ignoring informative
censoring in survival analysis and Markov models is biased estimation (Hillis, et al.,
1986). For the exponential survival function, the effect is to underestimate the hazard
and overestimate the median survival time (Lagakos, 1979). Ignoring informative
censoring in Markov models would intuitively effect estimation in the same way since
absorption probabilities would be underestimated.
Although not a focus of this investigation, Markov modeling is valid with left
censoring (Hillis, et al., 1986, Commenges, 1999). Left censoring, where subjects
enter the study at unknown stages of disease, is rarely documented in veterinary
clinical studies although it is quite common. Subjects enter a cohort at various stages
of a disease, rather than in the pre-diseased state or a specific state of disease. The first
observations from some subjects occur in early disease while first observations from
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others occur in more advanced stages of disease. Health states that account for
different disease stages can be incorporated into a Markov model and subjects can
enter the study in the appropriate health state (Commenges, 1999).
1.12 Estimation of Expected Survival
The duration of expected survival or life expectancy is common measure of
success for clinical studies and is the basis for clinical decision-making. Life
expectancy is defined as the average future lifetime of a cohort of subjects with
identical clinical features (Beck and Pauker, 1983). The Markov model can be used
to estimate life expectancy. For consistency and to use terminology more familiar to
veterinarians, the term “expected survival” is used. This term helps to convey that the
estimates are projected survival time. It is intuitive for any Markov process with at
least one absorbing state that can be reached from any transient state, that the
probability of eventual absorption is one (Beck, et al., 1982, Beck and Pauker, 1983,
Briggs and Sculpher, 1998, Bauerle, et al., 2000). For example, if the absorbing state
is death, eventually every subject dies. The sum of the expected duration time spent in
transient states before absorption modeled by the Markov process is the expected
survival of a cohort of subjects (Beck and Pauker, 1983, Briggs and Sculpher, 1998).
Expected survival estimated by Markov model analysis should be thought of as
an extrapolated survival under the assumption that the constant transition probabilities
continue to apply in the future (Silverstein, et al., 1988). Thus, expected survival is an
estimate based on the probability information obtained from an observed cohort. This
is in contrast to estimated median survival time derived from a survival function,
which is a summary of the survival times recorded for a cohort. Most veterinary
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clinical studies report median survival times estimated from Kaplan-Meier survival
function as a summary measurement for diseases and treatment outcomes.
Investigators often misinterpret this as expected survival for an individual, and
prognosis and selection of treatment for an individual is often based on this
measurement (Berg, et al., 1992, Blackwood and Dobson, 1996, Davidson, et al.,
1997, Crawshaw, et al., 1998, Dunning, et al., 1998, Khanna, et al., 1998).
Durations spent in transient states and expected survival can be estimated from
Markov models using matrix solution, cohort simulation and Monte Carlo simulation.
1.12.1 Fundamental Matrix Solution
Matrix solution provides an exact solution of the time spent in each state,
conditional on the entry state in which an individual enters the model. Matrix solution
is restricted to time homogeneous Markov chains. The transition probability matrix of
a chain that contains absorbing states is divided into four sections: Q contains
transition probabilities between transient states; R contains transition probabilities
from transient to absorbing states; O is a zero matrix, and I is an identity matrix
(Figure 1-6) (Beck and Pauker, 1983, Brown and Brown, 1990a).
Transient
States

To:
Absorbing
States

Transient
States

Q

R

Absorbing
States

O

I

From:

Figure 1-6 Separation of a probability transition matrix containing absorbing states
into 4 components -- Q contains transition probabilities between transient states; R
contains transition probabilities from transient to absorbing states; O is a zero matrix,
and I is an identity matrix.
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The average number of cycles that a subject resides in transient states before
absorption, given a specified starting state, is estimated from the fundamental (N)
matrix. Calculating N is the matrix algebraic equivalent of taking the inverse of the
transition probabilities in Q (Beck and Pauker, 1983, Brown and Brown, 1990b). The
N matrix specifies the average number of cycles that a subject resides in transient
states such that N = (I - Q)-1 where I is a identity matrix and Q is the square matrix of
the transient probabilities within P (Appendix I) (Beck and Pauker, 1983, Brown and
Brown, 1990b). Multiplication of the number of cycles by the length of the cycle gives
the expected duration in each state, conditional on a starting state. The sum of these
durations gives an estimate of expected survival, conditional on a starting state (Beck
and Pauker, 1983).
The variance of N is given by the V matrix with V = N(2N ′ − I ) − N 2 where N ′
is a copy of N with only the diagonal entries preserved (and zeroes elsewhere) and N 2
is a matrix with each entry of N squared (Appendix II) (Beck and Pauker, 1983,
Silverstein, et al., 1988). Each element of V represents the variance of the
corresponding element of N. The square root of each element of V is the standard
deviation of the corresponding element of N.
1.12.2 Markov Cohort Simulation
Cohort simulation uses a hypothetical cohort, for example 10,000 subjects, to
illustrate the predicted experience of subjects (Beck and Pauker, 1983, Sonnenberg
and Beck, 1993, Briggs and Sculpher, 1998, de Kruyk, et al., 1998, Bauerle, et al.,
2000). The entire cohort begins the model at time 0 in the initial disease state. If
necessary, the cohort can be distributed through several initial states. At each cycle, a
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vector of the distribution of the subjects among the states of the model is multiplied by
the transition probability matrix P and the adjusted vector of the distribution of the
subjects among the states of the model after one cycle is obtained. This is akin to
performing a transient analysis. Iterating the analysis for many cycles builds a profile
of the number of subjects expected in each state of the model over time. The process is
continued until there are no (or a restricted number) of subjects in the transient states.
The sum of subjects in each state over all simulation cycles is divided by the number
of subjects originally in the cohort to derive the mean number of cycles spent in each
state. The mean number of cycles, multiplied by the cycle length, estimates the mean
duration spent in each state, conditional on the starting state (Beck and Pauker, 1983,
Sonnenberg and Beck, 1993, Briggs and Sculpher, 1998). Again, the sum of the
durations spent in transient states is an estimate of the expected survival, conditional
on the starting state.
Cohort simulation enables a number of useful features. During the course of
analysis, adjustments for changes in the utility of the states can be made. This is useful
in cost-effectiveness studies (Briggs and Sculpher, 1998), but also in quality-of-life
studies where certain health states have different value to a subject than others (Gore,
1988). It is also possible to incorporate time-dependent probabilities and include halfcycle correction for long cycles (Beck and Pauker, 1983, Sonnenberg and Beck, 1993,
Briggs and Sculpher, 1998). Cohort simulation will not provide information on the
distribution or variance of the estimates (Beck and Pauker, 1983).
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1.12.3 Monte Carlo Simulation
Monte Carlo simulation passes hypothetical subjects through the Markov
process one by one. Monte Carlo simulation uses a random-number generator to
assign a value to each of the random variables (states) in accordance with its
probability distribution (transition probabilities) (Briggs and Sculpher, 1998,
Meerschaert, 1999a). Thus, the path of each subject will differ according to random
variation and repeated simulations can be considered independent random trials
(Meerschaert, 1999a). The subject is followed through the process until absorption.
The number of cycles until absorption allows estimation of the duration spent in each
of the health states and expected survival (Beck and Pauker, 1983). Monte Carlo
simulation is time consuming but allows considerable flexibility. Subjects can start in
different health states, varying utilities can be applied and time-dependent
probabilities can be incorporated. The variance of estimates is close-formed and easy
to calculate. Increasing the number of simulations will reduce the variance of the
estimates (Beck and Pauker, 1983, Briggs and Sculpher, 1998, Meerschaert, 1999a).
1.13 Interpretation of Estimates
Estimates of state durations and expected survival derived from matrix
solution, cohort simulation and Monte Carlo simulation give similar results if
equivalent transition probabilities and distributions are used, and if a large number of
life histories are generated with the Monte Carlo approach (de Kruyk, et al., 1998).
The variance of these estimates may vary. Cohort simulation is restrictive and cannot
generate a variance estimate. Monte Carlo simulation has the advantage of generating
variances very easily, which can be reduced by increasing the number of simulations.
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Matrix solution invariably generates large variance estimates, of the magnitude of the
estimated state durations (Silverstein, et al., 1988, Briggs and Sculpher, 1998). The
variances are analogous to the variance of a proportion. Although the probabilities
used in a Markov model may be calculated from a large sample with many subjecttime interval observations, precision is lost when the incidence rate is used to
approximate the probability of transition. Incidence rate approximation to the
transition probability can be used when the transition rate is small or the time interval
is short. However, for precision, the exact probability calculated from the incidence
rate should be used according to the formula p = 1 − e − λit where λi is the rate and t is
the time interval (Silverstein, et al., 1988). Estimates of expected survival are most
influenced by imprecision when the probability estimates are small since survival is
the inverse of the probability or rate.
Probability estimates used to construct models and estimates subsequently
derived from the model may include errors. Any model is only as good as the quality
of data used to build it (Beck, 1988). The precision of estimated probabilities depends
on the number of transitions and the duration of observations used to calculate the
probabilities. Imprecise estimates based on small numbers of transitions will have a
large effect on the estimates of state durations and expected survival (Silverstein, et
al., 1988). The problem of small numbers of transitions may be resolved by combining
states, if this does not violate the Markovian assumption (Silverstein, et al., 1988).
For the discrete Markov chain, the length of each cycle can overestimate or
underestimate state durations. Long cycles (years) have the most effect. The Markov
model assumes that the transitions occur between cycles and that subject membership
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of each state of the model is constant over the duration of each cycle. In reality,
subjects move between different states continuously. A half-cycle correction can be
used to avoid assumption that subjects move between states at the beginning or end of
a cycle (Sonnenberg and Beck, 1993, Briggs and Sculpher, 1998, Bauerle, et al.,
2000). This is equivalent to assuming that, on average, subjects move between states
in the middle of a cycle.
In a clinical study, it is unlikely that observations are always made at restricted
intervals. Transitions may be missed or erroneously assumed to occur at the time of
observation. Methods to accommodate these problems are mathematically intense but
the Markov model can be extended to situations where the observations are made at
regular time intervals, at irregular time intervals, or even to situations where the
observations are made at irregular intervals but the exact time of transition during that
interval is unknown (Marshall, 1990, Andersen, et al., 1991, Lawless and Yan, 1993,
Lee and Kim, 1998, Craig, et al., 1999). Because of their complexity, these
applications will not be addressed further.
1.14 Application in Veterinary Medicine
Various applications of Markov models have been reported in the veterinary
literature, primarily in large-animal population medicine. To date, there are no reports
of Markov models used to evaluate time-event data, or in particular, survival data,
from clinical studies in large or small animals.
Selected examples of the veterinary reports include the work of Oltenacu and
Natzke. In 1975, Oltenacu and Natzke used a Markov chain model to describe the
progression of mastitis in dairy cows (Oltenacu and Natzke, 1975). The model
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described seven infection states examined at monthly intervals. Simulation and costeffective analysis was used to examine the effect of mastitis on milk productivity.
In 1988, Carpenter described a microcomputer program that could be used to
model disease using Markov chains (Carpenter, 1988). Carpenter commented
commented on four studies that had been published after that of Oltenacua and
Natzke, which used Markov chains to describe disease processes in production
animals (Schwabbe, et al., 1977, Carpenter and Riemann, 1980, Lehenbauer and
Harmann, 1982, Zessin and Carpenter, 1985).
Ward and Carpenter published a series of reports describing construction of a
state transition model of the climatic factors and herd immunity affecting bluetongue
virus infection in Australian cattle (Ward and Carter, 1996a, Ward and Carter, 1996b,
Ward and Carpenter, 1997). The model used in these studies included sequential
matrices, the first representing the risk of infection in 10 age groups of cattle and the
second matrix represented transition between age groups and reproductive
performance. Climatic factors were regressed on the herd incidence to establish the
transition probabilities. Model validation was performed by comparing estimates to a
different observed cohort, and by sensitivity analysis (Ward and Carter, 1996a, Ward
and Carter, 1996b, Ward and Carpenter, 1997).
In 1988, Vonk Noordegraaf et al used a Markov chain to evaluate the spread
and control of infectious bovine rhinotracheitis in the Netherlands (Vonk Noordegraaf,
et al., 1998). A two-state model of non-infectious to infections was used to evaluate
the effect of vaccination strategies through a sensitivity analysis for 5 speculated
vaccination regimes. Cost analysis was also performed.
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More recently, Schlosser and Ebel (Schlosser and Ebel, 2001) used a Markov
chain and Monte Carlo simulation to estimate present disease prevalence from
historical data. This model was applicable to risk assessment in trade, food safety and
domestic animal-health regulations.
The only clinical application of Markov methods was the construction of
decision trees for estimating the value of removing an undescended testicle from a
young dog (Bosch, et al., 1989, Peters and van Sluijs, 2002). These investigations
used decision trees to determine the most valuable treatment. Interestingly, utilities
for the outcomes were based on life expectancy of dogs with various conditions. The
probability-adjusted utility of treatment options was consequently measured in years
of life expectancy (Peters and van Sluijs, 2002). This did not represent survival
estimation since the utilities were arbitrarily assigned, based on prior knowledge from
the literature.
1.15 Summary and Objectives for Present Studies
The Markov model is appealing for analysis of time-event data in veterinary
clinical studies for several reasons. Firstly, Markov models can describe the course of
disease as a series of probable transitions through several health or disease states. This
is an advantage over the restricted, two-state description of survival analysis. A
Markov model can accommodate informative censoring and competing risks by
addition of absorbing states. This offers a method to examine absorption by
euthanasia. Markov models allow estimation of expected survival based on the hazard,
that is, based on the future probability of dying, conditional on survival to the present.
This is a more clinically relevant measurement and easier for the veterinarian and
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owner to interpret. The graphic depiction of transient probabilities over time allows
an integrated view of the disease course and provides information for individual
decision-making. Assumptions of the Markovian property is required, but if
restrictive, can be met by addition of states to the model.
The work encompassed in this dissertation evolved from the dissatisfaction
with the current methods used to evaluate time-event data, in particular survival data,
in veterinary clinical studies. Almost all studies restrict analysis to Kaplan-Meier
estimation. Studies often violate underlying assumptions required for analysis, results
are seriously misinterpreted, and issues such as left-censoring are ignored. All
investigators choose to ignore the issue of observations from euthanized subjects.
Unfortunately, life-determining decisions are continually made based on the results
and interpretation of such studies and many veterinarians (and then owners), who are
not proficient epidemiologists or statisticians, are mislead.
The objectives of the studies presented in this dissertation were the following:
Study 1 – To illustrate how classification protocols for observations from
animals euthanized and dying will substantially influence the survival estimates using
Kaplan-Meier product limit estimation.
This study was important to highlight the inadequacy of using only KaplanMeier product limit estimation to evaluate veterinary clinical studies. Results of this
study showed that Kaplan-Meier product limit estimation of the survival function is
sensitive to classification protocols, particularly in the presence of a high frequency of
right-censored observations. It is clear that Kaplan-Meier estimation cannot be used
when there is informative censoring and hence is inadequate for accommodating
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observations from euthanized animals. In addition, it is clear that Kaplan-Meier
estimation does not provide information useful for individual decision-making or
prognostication. This is however, information that the veterinarian and client demand.
In the search for an alternate to Kaplan-Meier estimation, the application of Markov
modeling to describe disease was discerned as an appealing methodology.
The objectives of the second study followed naturally:
Study 2 - To describe the course of a chronic disease (canine lymphoma) using
a time-homogenous Markov chain. The Markov model would accommodate left
censoring through entry into different transient states, and informative right censoring
by inclusion of additional absorbing states. Estimates of expected survival would be
attained by matrix inversion or Monte Carlo simulation and would be compared to
estimates using Kaplan-Meier product limit methods.
The second study was important to explore the feasibility of using a simple
Markov model for a typical veterinary clinical data set. Results of the second study
showed that this methodology could be applied and achieve plausible results. Since
this data set was relatively small (although quite large compared to most veterinary
clinical studies), the intent was to explore the methodology and not the disease. Thus,
the third study was performed using a larger data set with the intent to say something
about the disease under investigation. In addition, different techniques in estimation
of transition probabilities, and in analysis of the data were used to gain familiarization
with techniques other than those used in the second study. The specific objectives of
the third study were:
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Study 3 – To construct a Markov model of the course of vaccine-associated
sarcoma in cats. The course of disease, predicted by the transition probability matrices,
would be compared for cats treated with different protocols. Estimates of expected
survival derived from Monte Carlo simulation would be compared and interpreted in
light of individual decision-making and treatment selection.
The third study was required so that the methodology could be applied to a
data set in a critical manner and information useful for individual decision making
could be derived. The study did provide relevant results and described the course of
the disease in an integrated way that has not been achieved by prior studies on that
particular disease.
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CHAPTER 2 THE EFFECTS OF DIFFERENT METHODS OF ACCOUNTING
FOR OBSERVATIONS FROM EUTHANIZED ANIMALS IN SURVIVAL
ANALYSIS*

*Reprinted from Preventive Veterinary Medicine, Vol 48, Hosgood G, Scholl DT: the
effects of different methods of accounting for observations from euthanized animals in
survival analysis, pp 143-154, Copyright (2001), with permission from Elsevier Science.
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2.1 Introduction
Survival time can be broadly defined as the time to the occurrence of a given
event. This event can be the development of a disease, response to a treatment, time to
relapse of disease, or (more traditionally) death (Lee, 1992a). Investigators often apply
survival analysis to clinical data to evaluate such event-times and also to determine if
there is a difference between these event-times for subjects grouped by different
characteristics.
The issue of euthanasia is unique to veterinary studies evaluating survival time.
The decision to euthanize an animal is based on several factors that include the health of
the animal, as well as factors such as age of the animal and cost of the treatment (Gobar,
et al., 1998, Mallery, et al., 1999).
Recent veterinary studies evaluating survival data have over 50% of the total
observations taken from euthanized animals (Cox, et al., 1991, Berg, et al., 1992, Munana
and Luttgen, 1998, Zwahlen, et al., 1998). The methods described to account for
observations from euthanized animals in these studies vary. Some investigators deleted
the observations (White, 1991). Some studies also deleted observations from animals lostto-follow-up (Johnson, et al., 1989). Most investigators equated the euthanized animals
with animals that died from the disease of interest during the study period (Prymak, et al.,
1988, Cox, et al., 1991, Schwarz, et al., 1991b, Schwarz, et al., 1991a, Berg, et al., 1992,
Spodnick, et al., 1992, Reeves, et al., 1993, Hammer, et al., 1995, Dunning, et al., 1998).
Other investigators gave no indication of the number of observations that came from
euthanized animals (McNiel, et al., 1997, Erhart, et al., 1998, Khanna, et al., 1998,
Lucroy and Madewell, 1999). Many investigators did not report how the observations
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from euthanized animals were specifically evaluated (Thompson and Fugent, 1992,
Straw, et al., 1996, Kuntz, et al., 1997, Munana and Luttgen, 1998, Wood, et al., 1998,
Zwahlen, et al., 1998) -- yet presented estimates of the median survival time and used this
information as the focus of the manuscript.
Although apparently more straight-forward, the issue of how to account for
observations from animals that die from causes other than the disease of interest is also
inconsistent. Because these animals do not die from the disease of interest, observations
from these animals should be right-censored – a right-censored or incomplete observation
is one from an animal that did not reach the outcome of interest during the study period
(Lee, 1992a). Some investigators determine death as the endpoint -- regardless of cause
(Khanna, et al., 1998). Intuitively, evaluating all observations as complete (that is, an
observation from an animal that did reach the outcome of interest during the study period)
-- regardless of the cause of death -- will result in erroneous inferences from the data.
Some investigators tried to address incomplete observations by right-censoring
observations from animals that were euthanized or died because of problems unrelated to
the disease of interest (Kosovosky, et al., 1991, Wallace, et al., 1992, Blackwood and
Dobson, 1996, Straw, et al., 1996, McNiel, et al., 1997, Dunning, et al., 1998). However,
these investigators still included observations from animals euthanized because of
problems related to the disease of interest as complete observations in the estimation of
median survival time. Also, observations from animals for which the cause of death or
euthanasia was unknown were included as complete observations -- possibly an attempt
to be conservative (Schwarz, et al., 1991a, Schwarz, et al., 1991b). Although the methods
used in these cited studies address incomplete observations, they still fail to resolve the
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issue that euthanasia is not an endpoint solely determined by disease pathology. Equating
observations from euthanized animals to complete observations from animals that died
from the disease of interest is inaccurate and will result in biased estimates of the survival
function and median survival time.
Two major issues are apparent: 1) there is bias in the estimation of survival time;
hence there should be lack of confidence in the inference from any survival analysis
when observations from euthanized animals are considered complete; and 2) because the
methods for evaluating the observations from euthanized animals (and animals that died
or were lost-to-follow-up) are inconsistent, the comparison of results between studies is
impossible. The objective of our study was to illustrate the effects of alternativeclassification protocols (for observations from euthanized animals and animals that died
of causes other than the disease of interest) on the estimate of the survival function and
median survival time.
2.2 Methods
For the purpose of this paper, the terminology “event-time” is used unless
specifically describing to the time to death, which is referred to as “survival time.”
2.2.1

Data Sets

Two real and one simulated data set were used as the basis of the investigation
(Table 2-1). The first two data sets (Canine and Feline) were taken from the veterinary
literature and were selected to include data that had a “typical” distribution of outcome
and a “typical” sample size of those published in the veterinary literature. The third data
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set (Sham) was simulated to have a distribution of outcomes different from the real data
sets – but still realistic for a veterinary clinical study.
Table 2-1 Data sets used to illustrate the effects of alternative methods of accounting for
observations from euthanized animals in survival analysis.
Outcome
Data set

Lost-tofollow-up

Alive at end
of study

Euthanized

Dead

No.

%

No.

%

No.

%

No.

%

0

0

35

50

30

43

5

7

disease

-

-

-

-

14

20

0

0

Unrelated

-

-

-

-

6

9

4

6

unknown

-

-

-

-

10

14

1

1

Data set Feline

3

9

3

9

16

50

10

31

disease

-

-

-

-

14

44

9

28

unrelated

-

-

-

-

0

0

1

3

unknown

-

-

-

-

2

6

0

0

Data set Sham

7

7

10

10

20

20

63

63

disease

-

-

-

-

15

15

43

43

unrelated

-

-

-

-

3

3

15

15

unknown

-

-

-

-

2

2

5

5

Data set Canine
N=70

N=32

N=100
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Each data set included a two-level stratification variable (either treatment or
tumor type) to allow investigation of the effect of the alternative protocols on betweenstrata comparisons. This feature was examined because most clinical studies are directed
at comparing treatments (or responses of different diseases or tumor types to the same
treatment) with a conclusion drawn according to such.
2.2.2

Data Set Canine

Data set Canine was acquired by the primary investigator from collaborators of a
previous investigation (Jaffe, et al., 2000). The raw data were used and any missing
survival times were replaced with randomly generated numbers between 1 and 1000
from a random-number table. The stratum variable referred to treatment. Survival time
was in days.
2.2.3

Data Set Feline

Data set Feline was acquired directly from published information (Cox, et al.,
1991) and again, any missing survival times were replaced with randomly generated
numbers between 1 and 30 from a random-number table. The stratum variable referred to
tumor type. Survival time was in months.
2.2.4

Data Set Sham

Data set Sham was created to have a greater proportion of animals that died from
the disease of interest and fewer animals alive at the end of the study than data sets
Canine and Feline -- but still have a moderate proportion of animals that were euthanized.
N = 100 was chosen to allow evaluation of a larger data set -- but use a number that is
attainable for a clinical study. After the outcome distribution was established, 100
observations within the range of 0 to 1000 days (to disperse the observations) were
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generated using a random-number feature of a statistical programa. A second list of
random numbers was generated and the observations were ordered according to this list.
The distribution of the outcome was then applied according to this order. A third list of
random numbers was generated and listed against the original observations for the
purpose of designating the stratum variable (eg. treatment, tumor type, animal
characteristic)–observations associated with an odd random number were applied to
stratum 1; observations associated with an even random number were applied to stratum
2.
2.2.5

Data Sets Sham 50, Sham 20, Sham 10

Because randomization is likely to produce strata within the simulated data set
that are not different, data set Sham was modified to create three new data sets with a predetermined difference in the magnitude of the observations between strata. The
observations for stratum 1 were multiplied by factors of 0.5, 0.8 and 0.9 to create data sets
Sham 50, Sham 20 and Sham 10 which had pre-determined differences between strata of
magnitude 50, 20 and 10% , respectively. The distribution of outcomes was unchanged.
2.2.6

Protocols

For each data set, seven alternative protocols for observations from animals that
were euthanized or animals that died were explored (Table 2-2). Protocols 1,4,5,6 and 7
were derived from methods described in published studies that either ignored (deleted)
observations from euthanized animals or animals that died from other causes, or equated
euthanized animals with those that died. Protocols 2 and 3 were explored to illustrate the
effect of right-censoring observations from animals that were euthanized or died from
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other causes. Incomplete observations from animals that were alive or lost-to-follow-up
were right-censored for all protocols (Lee, 1992a, Leung, et al., 1997).

Table 2-2 Methods of accounting for observations from euthanized or dead animals as
complete or right-censored (incomplete) using seven alternative protocols. Observations
from animals lost-to-follow-up or alive at the end of the study were considered rightcensored for each protocols. aA = all causes, D = disease of interest, U = unknown causes,
O = known causes other than the disease of interest, None = no observations from
animals with this event included in this definition. Note A=D+U+O

Definition
Protocol

1

2

3

4

5

6

7

Complete observations

Right-censored observations

Event

Causea

Event

Cause

Died

A

Died

None

Euthanized

A

Euthanized

None

Died

A

Died

None

Euthanized

None

Euthanized

A

Died
Euthanized

D+U

Died

O

None

Euthanized

A

Died

A

Died

None

Euthanized

None

Euthanized

A -- deleted

Died

D+U

Died

O -- deleted

Euthanized

None

Euthanized

A -- deleted

Died

A

Died

None

Euthanized

D+U

Euthanized

O

Died

D+U

Died

O

Euthanized

D+U

Euthanized

O
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2.2.7

Analysis

All survival functions were estimated using nonparametric Kaplan-Meier productlimit methods (Lee, 1992b). For each protocol, the survival functions for the two strata
were estimated and tested for homogeneity using the log-rank test. All tests for
homogeneity of survival functions were performed using a two-sided hypothesis against
the null hypothesis of homogeneity. Alpha was P < 0.05. For each protocol, the
stratum-specific estimates of median survival times with a 95% confidence interval
according to Greenwood’s formula (Greenwood, 1926) were generated. PROC
LIFETEST (SAS v6.12, SAS Institute, Cary, NC) was used for all analyses.
2.3 Results
All stratum-specific estimates and comparisons are summarized in Tables 3 to 8.
All protocols produced the conclusion of homogeneous strata for data sets Canine, Sham,
and Sham 10, and of non-homogeneous strata for data set Sham 50 (Table 2-3, Table 2-5,
Table 2-6). However, there was reversal of the magnitude of the point estimates for some
of the strata. (e.g. Data set Canine: the point estimate for stratum 2 was higher than for
stratum 1 with protocol 1 but the opposite for protocol 5, 6 and 7.)
The protocols altered the conclusions for stratum comparisons for data sets Feline
and Sham 20 (Table 2-4, Table 2-7, Figure 2-1). (e.g. Data set Sham 20: protocols 3 and
5 resulted in a conclusion of homogeneous strata while the other protocols resulted in a
conclusion of non-homogeneous strata.).
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Table 2-3 Comparisons of stratified survival-functions with the different protocols on
data set Canine. Survival time is in days. Data set taken from Jaffe et al., 2000. See
Table 2-2 for definitions of protocols. aCI = confidence interval; bNE = not estimable
because the probability of survival never decreased to 0.5
Stratum 1

Protocol

Median

95% CIa

Stratum 2

Censored

Median

95% CI

fraction %
1

692

2

b

Homogeneity
of strata
Censored
fraction %

(logrank P)

462, 1924

21/43 49

721

300, 874

14/27 52

0.44

NE

-

40/43 93

NE

-

26/27 96

0.99

3

NE

-

41/43 95

NE

-

27/27 100

0.34

4

NE

-

21/24 87

NE

-

14/16 88

0.50

5

NE

-

21/22 95

NE

-

14/14 100

0.48

6

1675

473, NE

24/43 56

821

300, NE

16/27 59

0.50

7

1924

473, NE

26/43 60

821

721, NE

18/27 67

0.76

Table 2-4 Comparisons of stratified survival-functions with the different protocols on
data set Feline. Survival time is in months. Data set taken from Cox et al., 1991. See
Table 2-2 for definitions of protocols. aCI = confidence interval; bNE = not estimable
because the probability of survival never decreased to 0.5
Stratum 1

Protocol

Median

95% CIa

Stratum 2

Censored

Median

95% CI

fraction %
1

2.5

Homogeneity
of
strata
Censored
fraction %

(logrank P)

0.8, 11

2/16 12

12.5

5, 33

4/16 25

0.03

b

2

11

3, NE

9/16 56

NE

-

13/16 81

0.04

3

11

3, NE

9/16 56

NE

-

14/16 88

0.01

4

3

0.8, NE

2/9 22

NE

-

4/7

57

0.07

5

3

0.8, 11

2/9 22

NE

-

4/6

67

0.03

6

2.5

0.8 , 11

2/16 12

12.5

5, 33

4/16 25

0.03

7

2.5

0.8 , 11

2/16 12

13

7, 33

5/16 25

0.02
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Table 2-5 Comparisons of stratified survival-functions with the different protocols on
data set Sham, a simulated data set with pre-determined, equivalent strata. Survival time
is in days. See Table 2-2 for definitions of protocols. aCI = confidence interval
Stratum 1

Protocol

Median

95% CIa

Stratum 2

Censored

Median

95% CI

fraction %

Homogeneity
of strata
Censored
fraction %

(logrank P)

1

550

402, 735

9/50 18

574

482, 710

8/50 16

0.92

2

677

496, 865

18/50 36

619

488, 839

19/50 36

0.95

3

810

578, 963

28/50 56

710

504, 909

24/50 48

0.53

4

578

391, 810

9/41 22

499

382, 632

8/39 20

0.45

5

578

285, 810

9/31 29

504

430, 632

8/34 24

0.59

6

553

417, 750

10/50 20

580

482, 731

10/50 20

1.00

7

640

523, 886

20/50 40

619

488, 788

15/50 30

0.54

Table 2-6 Comparisons of stratified survival-functions with the different protocols on
data set Sham 50, a simulated data set with stratum 1 having a predetermined 50% lower
median survival time compared to stratum 2. Survival time is in days. See Table 2-2 for
definitions of protocols. aCI = confidence interval
Stratum 1

Protocol

Median

Stratum 2

95% CIa

Censored

Median

Homogeneity
of strata
95% CI

fraction %

Censored

(log-

fraction %

rank P)

1

275

202, 68

9/50 18

574

482, 710

8/50 16

0.0001

2

338

248, 432

18/50 36

619

488, 839

19.50 36

0.0001

3

405

289, 482

28/50 56

710

504, 909

24/50 48

0.008

4

289

196, 405

9/41 22

499

382, 632

8/39 21

0.0001

5

289

142, 405

9/31 29

504

430, 632

8/34 24

0.0001

6

276

208, 375

10/50 20

580

482, 731

10/50 20

0.0001

7

320

262, 443

20/50 40

619

488, 788

15/50 30

0.0001
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Table 2-7 Comparisons of stratified survival-functions with the different protocols on
data set Sham 20, a simulated data set with stratum 1 having a predetermined 20% lower
median survival time compared to stratum 2. Survival time is in days. See Table 2-2 for
definitions of protocols. aCI = confidence interval
Stratum 1

Protocol

Median

95% CIa

Stratum 2

Censored

Median

95% CI

fraction %

Homogeneity
of strata
Censored
fraction %

(logrank P)

1

440

321, 588

9/50 18

574

482, 710

8/50 16

0.008

2

542

396, 692

18/50 36

619

488, 839

19/50 36

0.02

3

648

462, 770

28/50 56

710

504, 909

24/50 48

0.26

4

462

313, 648

9/41 22

499

382, 632

8/39 20

0.08

5

462

228, 648

9/31 29

504

430, 632

8/34 24

0.16

6

442

334, 600

10/50 20

580

482, 731

10/50 20

0.005

7

512

418, 788

20/50 40

619

488, 788

15/50 30

0.07

Table 2-8 Comparisons of stratified survival-functions with the different protocols on
data set Sham 10, a simulated data set with stratum 1 having a predetermined 10% lower
median survival time compared to stratum 2. Survival time is in days. See Table 2-2 for
definitions of protocols. aCI = confidence interval
Stratum 1

Protocol

Median

Stratum 2

95% CI

Censored

Median

Homogeneity of
strata
95% CI

fraction %

Censored

(log-

fraction %

rank P)

1

495

362, 662

9/50 18

574

482, 710

8/50 16

0.11

2

609

446, 778

18/50 36

619

488, 839

19/50 36

0.15

3

729

520, 867

28/50 56

710

504, 909

24/50 48

0.59

4

520

352, 729

9/41 22

499

382, 632

8/39 20

0.40

5

520

256, 729

9/31 29

504

430, 632

8/34 24

0.47

6

498

375, 675

10/50 20

580

482, 731

10/50 20

0.09

7

576

471, 797

20/50 40

619

488, 788

15/50 30

0.34
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Figure 2-1 Estimated survival functions S(t) for strata with protocol 3 (top) and protocol 6
(bottom) for data set Sham 20, a simulated data set with stratum 1 having a predetermined 20% lower median survival-time compared to stratum 2. Protocol 3, required
right-censoring observations from euthanized animals and resulted in conclusion of
homogeneous strata (P=0.26). Protocol 6 required classing observations from euthanized
animals as complete, except if they were euthanized for reasons other than the disease of
interest (right-censored), and resulted in a conclusion of non-homogeneous strata
(P=0.005).
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2.4 Discussion
Although there were some overlaps in the 95% confidence intervals for the
estimates of median survival time with the different protocols, viewing only the point
estimates in the results of our study would result in quite different conclusions. In
veterinary oncology, when survival times are not always long and often described in
months,(Cox, et al., 1991, Blackwood and Dobson, 1996, Ettinger, et al., 1998) the
difference of one or two months in a point estimate may be important. Within each data
set, the protocols that required deletion of observations (protocols 4 and 5) typically
resulted in lower point estimates of median survival time.
In comparison, the protocols that required a substantial number of censored
observations (protocols, 2,3,6 and 7) often had higher point estimates of median survival
time. This discrepancy is important. Deleting observations deletes important data from
any study, and consequently presents a misleading point estimate of survival time.
Deleting censored observations has been shown to underestimate the survival function
and estimates of survival time (Watt, et al., 1996). Our results support this finding
although how much of an underestimate the result represents is unclear because the true
estimate is unknown. The powerful feature of survival analysis is that it has the ability to
use information from observations that are incomplete (Lee, 1992a, Watt, et al., 1996);
hence, protocols that delete such observations are unsatisfactory.
Inherent to survival analysis is the reduction in confidence for the estimation of
the upper tail of the survival distribution because the sample size progressively decreases
over time (Kleinbaum, 1996). Consequently, the median is the preferred measure of
central tendency when there are right-censored observations (Kleinbaum, 1996).
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Protocols that required substantial right-censoring of observations frequently resulted in
the inability to obtain estimates of median survival time because the probability of
survival did not decrease below 0.5. The inability to obtain estimates can pose problems
for clinical studies that rely on estimates to summarize results and relay prognostic
information. Typically, as shown with the data sets in this study, veterinary studies can
contain a large proportion of euthanized animals. In addition, there may be a moderate
proportion of animals lost to follow-up, or that die of other causes (Shapiro, et al., 1988,
Cox, et al., 1991, Berg, et al., 1992, Munana and Luttgen, 1998, Zwahlen, et al., 1998).
Such studies are vulnerable to problems of unobtainable estimates when protocols that
require right-censoring of observations are used.
The reversal in ranking of strata appeared most often between protocols requiring
some right-censoring (protocol 6,7) or no separation of cause of death (protocol 1) and
protocols requiring deletions (protocol 2,3). This reversal in the estimates shows the
danger of deleting observations and how right-censoring will increase the estimates in
comparison to deletion (Watt, et al., 1996).
The most-important assumption of any censoring is that of independence, such
that the survival time and the time of censoring are independent (Leung, et al., 1997).
Independent censoring should be non-informative, and non-prognostic. (That is, a
censored observation at time C indicates that the survival time exceeded C but gives no
prognostic information about subsequent survival times of that animal or of other
animals.) To clarify right-censoring under these terms, it is easy to see that rightcensoring due to study termination is likely to be independent of survival time; however,
right-censoring due to other reasons such as loss-to-follow-up might not be independent
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of survival time. Right-censoring due to euthanasia is certainly not independent of
survival time. If censoring is informative (not independent), then standard Kaplan-Meier
product limit methods of estimation of the survival function is biased and methods that
account for the informative nature of the observations must be used (Robins, 1995b,
Robins, 1995a, Leung, et al., 1997). If the censoring time and the survival time are
positively correlated, the Kaplan-Meier estimate will over-estimate the survival function;
if the times are negatively correlated, then the Kaplan-Meier estimate will under-estimate
the survival function (Leung, et al., 1997). Thus, right-censoring observations from
euthanized animals (due to the disease) is inappropriate when the standard methods of
survival analysis are applied (Fisher and Kanarek, 1974).
One investigator proposed that to avoid the issue of euthanasia in analysis of
veterinary oncology studies, the time to tumor recurrence should be used to evaluate the
efficacy of treatment (Theon, et al., 1993). While this may avoid the issue of observations
from euthanized animals, it only provides partial information on the effect of the tumor
type or treatment, etc. More importantly however, the estimation of the survival function
or time-to-tumor-recurrence function may still be biased. Most veterinary studies use
right imputation of observations. The observations are collected at intervals over time
(usually associated with re-visits). When observations are treated as point observations
(which requires continuous observation), it is assumed that the occurrence of the event
coincides with the reporting of the event (right imputation). In reality, the simultaneous
occurrence of the event and the re-visit is unlikely and making the assumption of
coincidence will lead to biased estimates (Leung, et al., 1997). Right imputation has more
effect when the intervals are wide and represent a substantial proportion of the overall
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observation period (Leung, et al., 1997), or when the intervals are not independent of the
event (e.g. a revisit is prompted by a change in the animal’s condition).
2.5 Conclusion
The protocols applied in current veterinary studies to account for observations
from euthanized animals, and in some cases, from animals that die or are lost-to-followup, are inadequate and likely to present biased results. When observations from animals
that are euthanized are used as complete observations -- even if the protocols applied are
the same between studies -- the equation is erroneous because euthanasia as an arbitrary
end point (and, hence, inconsistent among studies and even among observations). Rightcensoring observations from animals that are euthanized would provide uniformity
among investigations; however, methods of analysis that account for the informative
nature of the time-of-euthanasia must be used.
2.6 Notes
a

SAS Version 6.12, SAS Institute, Cary, NC.
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CHAPTER 3 ESTIMATION OF HEALTH-RELATED SURVIVAL USING A
MARKOV MODEL IN A COHORT OF DOGS WITH GENERALIZED
LYMPHOMA
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3.1 Introduction
One of the most common measurements used to describe clinical disease,
particularly cancer, is survival time or time to other important event such as tumor
recurrence (Thompson and Fugent, 1992, Hammer, et al., 1995, Al-Sarraf, et al., 1996,
Straw, et al., 1996, Kuntz, et al., 1997, Levy, et al., 1997, Slawienski, et al., 1997,
Khanna, et al., 1998, Zwahlen, et al., 1998). There has been recent concern over how
some clinical studies published in the veterinary literature have been interpreted
(Pitson, 2000). Time-event studies, collectively known as “survival studies” present
two concerns: 1) survival estimates may contain substantial inherent bias, as
demonstrated recently by the authors, (Hosgood and Scholl, 2000) and 2) survival
estimates provide only quantitative estimates of the survival time.
Most veterinary studies evaluate time-event data using non-parametric KaplanMeier product limit estimation (Thompson and Fugent, 1992, Al-Sarraf, et al., 1996,
Blackwood and Dobson, 1996, Kuntz, et al., 1997, Levy, et al., 1997, Dunning, et al.,
1998, Khanna, et al., 1998) or Cox proportional hazards estimation (Johnson, et al.,
1989, Spodnick, et al., 1992, Hammer, et al., 1995, Slater, et al., 2001). Unfortunately,
the Kaplan-Meier estimator is sensitive to methods of classifying euthanized animals,
animals lost to follow-up, or in some cases, animals dying from other causes (Hosgood
and Scholl, 2000). Euthanasia represents an arbitrary end point determined by the
owner and veterinarian (Gobar, et al., 1998, Mallery, et al., 1999) and does not
precisely equate to the time of natural death. In an attempt to manage the problem,
investigators have used a variety of protocols, including deleting or censoring such
observations or simply equating them with death (Al-Sarraf, et al., 1996, Kuntz, et al.,
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1997, Dunning, et al., 1998, Khanna, et al., 1998). These protocols yield biased and
misleading estimates of survival time (Hosgood and Scholl, 2000). While censoring
observations from euthanized animals appears a plausible solution, such observations
are informative and neither Kaplan-Meier or Cox proportional hazards estimation are
appropriate since the underlying assumption of these methods is that censoring is
uninformative, that is, independent of survival time (Collett, 1994). Interestingly,
some investigators deny that a problem exists and dismiss observations from
euthanized animals as being usual for any clinical data set and hence the variability
this presents is natural (Slater, et al., 2001).
A survival estimate provides a quantitative description of the course of the
disease till the recognized outcome, which can be used as a measurement to compare
treatment success or failure. However, it conveys no information of the animals’
condition during the survival time. The animals’ health and well-being, particularly
under alternative treatments, are issues that are very important to veterinarians and
owners and may substantially influence decision making.
An alternate strategy to evaluate time-event data is the use of Markov
modeling. Markov modeling is a form of stochastic modeling (one which models
random events) used in diverse fields areas such as computer science, engineering,
mathematics, genetics, agriculture economics, education and biology (Hillis, et al.,
1986, Jain, 1986, Stewart, 1994). Markov modeling has received considerable
attention in the evaluation of human disease. For example, it has been used in the
evaluation and description of diabetic retinopathy (Marshall and Jones, 1995),
systemic lupus erythematosus (Silverstein, et al., 1988), renal disease (Schaubel, et al.,
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1998), papilloma virus and human immunodeficiency virus (Hendriks, et al., 1996).
Markov modeling is the basis for decision making analysis (Sonnenberg and Beck,
1993). As evaluation of quality–of-life and health-related states in human cancer
studies is explored (Bowling, 1995, Bradlyn and Pollock, 1996, Bowling, 1997,
Glasziou, et al., 1998), Markov modeling continues to be the basis for evaluation of
such data (Olschewski and Schumacher, 1990, Stewart, et al., 1998, Ng, et al., 1999,
Aoki, et al., 2000).
The intent of this study was to create a Markov model to describe the healthrelated survival in a cohort of dogs with generalized lymphoma and use the model to
estimate survival time. The cohort contained a substantial number of animals that were
euthanized or were lost to follow-up.
3.2 Methods
3.2.1

Data

Data from the medical records of 64 cases of generalized lymphoma seen at
Louisiana State University Veterinary Teaching Hospital and Clinic between 1990 and
2000 was used for this study. Inclusion criterion was that the dog had a diagnosis of
generalized lymphoma confirmed by histology or cytology.
Information extracted from the records included clinical signs and hematologic
data. This data was entered into a data basea and used for health-state classification.
Each visit for each dog represented a single record.
3.2.2

Health State Definition, Classification and Validation

Five health states were defined: two transient states and three absorbing states
(Table 3-1).
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Table 3-1 Definition of health states to describe dogs with lymphoma. *TOXIC =
presence of clinical or hematologic changes; **WELL = absence of clinical signs or
hematologic changes.
State

Definition

Type

TOXIC*

Toxic

Transient

WELL** Well

Transient

EUTH

Euthanized

Absorbing

DEAD

Dead

Absorbing

LTF

Lost to follow-up

Absorbing

The definition of TOXIC was based on previous discussion of toxicity with
lymphoma (Table 3-2) (van Vechten, et al., 1990, Hahn, et al., 1992, Moore, et al.,
1994, Ruslander, et al., 1994, Myers III, et al., 1997, Khanna, et al., 1998, Lucroy, et
al., 1998, Zemann, et al., 1998, Lucroy and Madewell, 1999, Frimberger, 2000).
The definition of health states was constructed such that the states were
mutually exclusive. A dog was classified in TOXIC if one or more of the hematologic
or clinical abnormalities listed were present (Table 3-2). A dog was classified in
WELL is none of the hematologic or clinical abnormalities listed were present (Table
3-2). TOXIC represented a state where there are moderate to severe clinical signs that
compromise the animal or where hematologic changes are severe enough to have an
impending impact on the dogs health and the likelihood of continued treatment. There
was no attempt to differentiate whether toxicity was a result of treatment or disease.
There was no attempt to determine whether WELL represented a disease-free or
remission state, or a state where the animal was tolerating the disease.
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Table 3-2 Definition of toxicity (TOXIC) health state classification. Presence of one or
more of these conditions was sufficient to classify a animal as TOXIC.
*Lymphadenopathy was not considered a toxic change.

Condition representing toxicity *

Definition

CLINICAL SIGNS
Body weight

Weight loss on history of presentation
Weight loss >5% since last visit

Vomiting

>3 times per day or requiring fluid therapy
for > 2 days

Diarrhea

Persistent (>3 days) or requiring fluid
therapy for > 2 days

Appetite

Complete anorexia

Activity

Inactivity – not willing to move around
voluntarily except to defecate or urinate

Cardiac toxicity

Clinical signs of cardiac failure and
echocardiographic evidence of decreased
contractility with or without heart chamber
enlargement

HEMATOLOGY
Platelets

<125,000 cells/dl

Red blood cells

PCV < 25%

Blood urea nitrogen

>50 g/dl

White blood cells

<3500 cells/dl

Neutrophils

<2500 cells/dl

SUPPORTIVE CARE
Fluid therapy > 2 days
Any other condition requiring intensive
care hospitalization >2 days
A subset of 15 cases (58 cycles) were classified by two other veterinarians to
evaluate the agreement between raters. Calculation of the chance corrected agreement
allowed estimation of misclassification due to imprecision using the scheme (Dunn,
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1989). In addition, these cases were re-classified by the PI and two veterinarians at
least one month later to estimate intra-rater repeatability (intraclass correlation
coefficient) (Rosner, 1995) of the classification scheme.
3.2.3

Markov Estimation and Analysis

A 5 state, discrete, time homogeneous Markov chain was constructed. Each
dog’s survival interval was divided into 7-day cycles that were assigned a single
health-state (Figure 3-1).

WELL

TOXIC

EUTH

DEAD

LTF

Figure 3-1 Five state Markov chain with two transition states (TOXIC, WELL) and
three absorbing states (EUTH = euthanized, DEAD = died due to disease, LTF = lostto-follow-up).
The transitions of the Markov chain were summarized by constructing a
transition probability matrix. The progression of the disease was described by a
transition analysis of the Markov chain that required sequential multiplication of the
transition probability matrix. The probability matrix was then manipulated to estimate
residence (survival) times in each state and subsequently summed to estimate overall
survival time. For comparison purposes, Monte-Carlo simulation of the Markov chain
based on the estimated transition probabilities was also performed to generate
estimates of survival times.
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3.2.4

Probability Matrix

For each cycle, a count matrix was constructed based on the number of dogs
making the respective transitions. The count matrices were summated to give the
overall summation (S) matrix (Jain, 1986). The summation matrix was used to
construct the probability (P) matrix using maximum likelihood estimates of pˆ ij , the
probability of transition from state i, the previous state, to state j, the future state,
given by pˆ ij = f ij ( k ) f i. ( k ) where fij is the frequency or count of dogs making the
transition from state i to state j, fi. is the sum of dogs initially in state i and k is the
cycle with a total of K cycles (Figure 3-2) (Craig and Sendi, 2001). Hence, the sum of
each row of the P matrix is one (Jain, 1986).
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∑
f15 ( k )  f1.
∑

k =1

K
f 25 ( k )  f 2.
∑

k =1

.


.

K
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LTF

K

TOXIC WELL EUTH DEAD LTF ∑

TOXIC
p11
p12
.
.
p15  1

 WELL
p21
p22
.
.
p25  1
P=

.
.
.
.
.  1
 EUTH
 DEAD
.
.
.
.
.  1


p51
p52
.
.
p55  1
 LTF
Figure 3-2 Summation matrix (S) and probability matrix (P).
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3.2.5

Time Homogeneity Assumption

The assumption of homogeneity of transition probabilities across time cycles
was tested using the likelihood-ratio chi square statistic which tests the parameter
values that maximize the likelihood function under the assumption that the null
hypothesis (there is homogeneity across time strata) is true (Kalbfleisch and Lawless,
1985, Jain, 1986, Agresti, 1996). Thus, the test is based on the ratio of the maximized
likelihoods when parameters satisfy the null hypothesis to the maximum likelihood
when the parameters are unrestricted (in the sample).
The assumption of homogeneity was evaluated over all cycles and within
certain periods (cycles 1-25, cycles 26-50 and cycles 51+). In addition, the data was
collapsed for each of the above periods, and the assumption of homogeneity was
evaluated across the three periods.
3.2.6

N Step Transition Analysis

The progression of the disease can be described by performing a transition
analysis (Silverstein, et al., 1988). The probability of being in a given state after n
steps or cycles is calculated by P n where n is the number of cycles. The N-step
transition analysis was performed over successive cycles until absorption was
complete. The probabilities of being in each transient or absorbing state, was recorded
at each cycle.
3.2.7

Residence (Survival) Time in Each Transient State

An estimate of the overall survival time can be made by summing the
estimated average number of cycles that an animal resided in both of the transient
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states. The average number of cycles that an animal resided in either of the transient
states was estimated using matrix algebra and Monte Carlo simulation (Beck and
Pauker, 1983, Sonnenberg and Beck, 1993, Briggs and Sculpher, 1998, Meerschaert,
1999).
Matrix algebra - The transition probability matrix of a chain that contains
absorbing states can be divided into four sections: the section labeled Q reflects the
probability of not being absorbed, conditional on the starting state; the section R
reflects the probability of being absorbed; the section O is a zero matrix, and section I
is an identity matrix (Figure 3-3) (Beck and Pauker, 1983, Brown and Brown, 1990a).
To:
Transient
States

Absorbing
States

Transient
States

Q

R

Absorbing
States

O

I

From:

Figure 3-3 Separation of a probability transition matrix containing absorbing states
into 4 components -- Q is the probability of not being absorbed, conditional on the
starting state; R is the probability of being absorbed; O is a zero matrix, and section I
is an identity matrix.
The average number of cycles that an animal resided in either transient state
before absorption, given a specified starting state, was estimated from the fundamental
(N) matrix. Calculation of N is the matrix algebraic equivalent of taking the inverse of
the transition probability (Beck and Pauker, 1983, Brown and Brown, 1990b).
Calculation of N is explained by Beck (Beck and Pauker, 1983). N specifies the
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number of cycles that animals resided in the transient states such that N = ( I - Q )

-1

where I is the identity matrix and Q is the square matrix of the transient probabilities
within P (Appendix I) (Beck and Pauker, 1983, Brown and Brown, 1990b).
The variance of N is given by the V matrix with V = Ν ( 2Ν ′ - Ι ) - Ν 2 where
N ′ is a copy of N with only the diagonal entries preserved (and zeroes elsewhere) and
N 2 is a matrix with each entry of N squared (Appendix II) (Beck and Pauker, 1983,
Silverstein, et al., 1988). Each element of V represents the variance of the
corresponding element of N. The square root of each element of V was used as the
standard error of the corresponding element of N.
Estimation of residence/survival times by Monte Carlo estimation - One
hundred simulations were started from TOXIC and 100 simulations were started from
WELL, each continuing until the chain terminated in an absorbing state (Beck and
Pauker, 1983, Briggs and Sculpher, 1998, Meerschaert, 1999). The mean residence
time in each transition state, conditional on the starting state, was calculated from the
individual transition simulations. The mean survival time, conditional on the starting
state was calculated from the sum of the residence time in each transition state from
the individual transition simulations. A weighted mean of the conditional survival
times was then calculated to give an overall survival time, weighted according to the
distribution of the starting states in the cohort; that is the conditional survival time for
starting in TOXIC was weighted by a factor of 0.5625 and the conditional survival
time for starting in TOXIC was weighted by a factor of 0.4375 before summing the
two estimates. The variance of this weighted estimate was calculated as the variance
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of a sum; σ 2 ( aX + bY ) = a 2σ 2 ( X ) + b 2σ 2 (Y ) + 2abσ ( XY ) (Neter, et al., 1982) and
used to calculate the 95% confidence interval of the weighted estimate. The frequency
of absorption into the three different absorbing states, conditional on the starting state,
was recorded.
All matrix manipulations were performed using MatLabb and Markov Chain
Add-in for Excel Spreadsheetsc.
3.2.8

Survival Analysis

Survival analysis was also performed to compare and contrast with Markov
model analysis. Kaplan-Meier product limit estimation of a survival function of the
cohort was performed using PROC LIFETESTd. Observations from dogs that were
lost to follow-up or died due to other causes were right censored (Lee, 1992a).
Observations from all dogs that were euthanized and dogs that died due to lymphoma
were considered complete. The mean and median survival times were estimated from
the survival function.
3.2.9

Verification of Markov Estimates

A valid estimate of the survival time can only come from complete
observations. With such data, the estimate of the mean survival time using KaplanMeier product limit methods will equal the true arithmetic mean of the observations.
Thus, estimates derived from a Markov model constructed from complete observations
should be similar to the arithmetic (and Kaplan-Meier estimate) of survival time. To
verify the estimates of residence time from the discrete, time homogenous Markov
model used in this study, observations from the subset of dogs that died (n=16) were
used to construct the “dead” probability matrix (Pd) and its fundamental matrix (Nd).
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In addition, using the probabilities from Pd to perform Monte Carlo simulation, 100
simulations were performed starting from TOXIC and 100 simulations were
performed starting from WELL, continuing until the chain terminated in an absorbing
state (Beck and Pauker, 1983). The mean residence time in each transition state, and
survival times, conditional on the starting states, were estimated. A weighted mean
overall survival time was then calculated as described previously. The Markov
estimates of the survival time were compared to the 95% confidence interval of the
mean and median survival times of the restricted cohort estimated from the KaplanMeier product limit analysis.
3.3 Results
3.3.1

Health State Testing

There was 100% agreement in health state classification among the 3 raters
indicating there was very little chance of misclassification. In addition, intra-rater
agreement was 100%, indicating the health state classification was repeatable within
raters.
3.3.2

Markov Modeling

Data from 64 dogs was included for all analyzes. Thirty-six dogs (56.25%)
entered the study in TOXIC and 28 dogs (43.75%) entered in WELL. There were a
total of 1218 transitions with an average of 19.03 transitions per dog. The maximum
number of transitions by any dog was 167. During the progression of disease, many
transitions were made back and forth between TOXIC and WELL. Sixteen dogs (25%)
died due to lymphoma, 30 dogs (47%) were euthanized and 18 dogs (28%) were lost
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to follow-up. Of the dogs lost to follow-up, 10 dogs were in TOXIC and 8 dogs were
in WELL.
3.3.3

Probability Matrix

The S and P matrices are shown in Figure 3-4.
Toxic Well Euth Dead LTF ∑

 Toxic 231
53
19
10
10  323

 Well
57
813
11
6
8  895
S=

0
0
0
0
0  0
 Euth
 Dead
0
0
0
0
0  0


0
0
0
0
0  0
 LTF
Toxic Well Euth Dead LTF  ∑

Toxic 0.715 0.164 0.059 0.031 0.031 1


 Well 0.064 0.908 0.012 0.007 0.009  1
P=

0
0
1
0
0 1
 Euth
 Dead
0
0
0
1
0 1


0
0
0
0
1  1
 LTF
Figure 3-4 Summation (S) and transition probability (P) matrices.
3.3.4

Time Homogeneity Assumption

Evaluation across the entire number of cycles did not result in rejection of the
null hypothesis of homogeneity at P<0.05 (χ2=628, df=1458) however the validity of
the test is questioned since the density of the data is thin, particularly in the later
cycles. When the data was divided into three periods, from cycles 1-25 (54% of data,
26-50 (23% of data) and 50+ (26% of data), the null hypothesis of homogeneity across
cycles within each period was not rejected at P<0.05 (χ2=193, df=207; χ2=96, df=168;
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χ2=223, df=707 respectively). When the data was collapsed within each of these
periods, the null hypothesis of homogeneity across these periods was not rejected at
P<0.05 (χ2=23, df=18). Thus, for the purposes of this investigation, the assumption of
homogeneity of transitions over time was considered satisfied.
3.3.5

N Step Transition Analysis

The probabilities of being in any one state at any time (step) are displayed
graphically in Figure 3-5. Complete absorption occurred by 100 cycles.

Euth
Dead

LTF

1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0

Cycles (7 days)

40
60
8
100
120
5

//
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Probability

Toxic
Well

Figure 3-5 N step transition analysis of a Markov model of canine lymphoma
depicting progression of the disease. The health states TOXIC, WELL, EUTH
(euthanasia), DEAD (dead) and LTF (lost-to-followup) are defined in Table 3-1 and
Table 3-2.
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Note that the probabilities of residing in a transient state decrease over time
and the probability of absorption increase such that eventually all animals are
absorbed. Starting in TOXIC, the probabilities of being in TOXIC are higher initially,
but after 4 steps (28 days), the probability of being in WELL is higher. The
probability of being in WELL then dominates until step 14 (98 days). Thus, even if
the dog presents in the TOXIC, the longer the dog lives, the more likely it is to reside
in WELL. After step 14, the probability of being euthanized is highest and remains the
highest for all absorbing states. Note that as time goes on, the probability of dying or
being LTF also increases but remains less than that for euthanasia.
Starting in WELL, the probability of being in WELL remains much higher
than had the dog entered in TOXIC. The probability of being in WELL remains higher
than being in TOXIC for the entire analysis. At step 23 (161 days), the probability of
being in Euthanasia exceeds that of being in WELL and remains the highest for all
absorbing states. At step 31 (217 days) the probability of DEAD exceeds that of being
in WELL. Again, as time goes on, the probability of being LTF increases.
3.3.6

Residence Time in Each Transient State

Matrix inversion - The estimated mean number of cycles an animal resided in
each transient state given by N and the variance and standard error of those estimates
given by V and SE are shown in Figure 3-6. After multiplying the estimated number
of cycles by 7, the estimated residence times and 95% confidence intervals in days are
shown in Figure 3-7.
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TOXIC WELL 
TOXIC WELL 





5.86
10.49  V = TOXIC
N = TOXIC
2.01
8.54 
 WELL
 WELL
4.07
18.20 
1.75
14.04 
TOXIC WELL 


1.17
1.77 
SE =  TOXIC
 WELL
0.36
3.66 
Figure 3-6 Estimated mean number of cycles (N) an animal resided in each transient
state. V is the variance and SE is the standard error of those estimates.

∑




TOXIC
WELL


41
73

 114
N(days) = TOXIC

(25-57)
(49-98)  (74 − 155)


 156
28
127
 WELL

(24 − 33 (77 − 178)  (101 − 211)

Figure 3-7 Estimated mean number of days (95% Confidence interval) an animal
resided in each transient state.
Thus, a dog starting in TOXIC was estimated to survive 114 days (95%CI 74155), and starting in WELL 156 days (95% CI 101-211). Weighting these conditional
survival times according to the distribution of dogs starting the study in each state (ie.
114.4 x 0.5625 + 155.9 x 0.4375), gave a weighted survival time of 133 days.
Estimation of residence/survival times using Monte Carlo simulation - The
estimated survival time, derived from summation of residence times in both transient
states, conditional on starting the chain in TOXIC was 105 days (95% CI 82-128)
(Table 3-3). This was shorter than the estimate conditional on starting the chain in
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WELL which had a mean survival time of 137.8 days (95% CI 112-164). The
weighted overall survival time was 119 days (95% CI 110-128). The absorbing state
for observations starting in TOXIC was 50 EUTH, 25 DEAD and 25 LTF. The
absorbing state for observations starting in WELL was 48 EUTH, 31 DEAD and 21
LTF.
Table 3-3 Mean estimated residence times (95% Confidence interval) in specified
heath states given a specified starting state. The weighted mean, based on the
distribution of starting states in the cohort, was used to calculate the estimated of the
weighted overall survival time.
Starting Residence in Residence in
state
TOXIC
WELL

Conditional
survival

TOXIC 28 days
(n=100) (22-34)

77 days
(55.6-97.4)

105 days
(82-128)

WELL 27 days
(n=100) (20-33)

111 days
(88-134)

138 days
(112-164)

3.3.7

Weighted overall
survival
119 days
(110-128)

Survival Analysis

Kaplan-Meier estimation - No dogs died or were euthanized for causes other
than lymphoma. Kaplan-Meier estimation of the survival curve with all observations
from dogs dying or euthanized considered complete, and observations from dogs lostto-follow-up right censored resulted in a point estimate of the median survival time as
72 days (95% confidence interval 58-152 days). The mean survival time was 201 days
(95% confidence interval 119-284 days). Forty-six observations were complete and 18
observations were right censored (28.1%) (Figure 3-8).
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Figure 3-8 Kaplan-Meier product limit estimation of the survival function for canine
lymphoma where observations from records terminating in euthanasia or death due to
lymphoma were considered complete. Observations from dogs lost-to-followup were
right censored. No dogs died from other causes.
3.3.8

Verification of Residence Time Estimates

Utilizing the subset of dogs that died, twelve of these dogs (75%) entered the
study in TOXIC, 4 dogs (25%) entered in WELL. The Sd and Pd are shown in Figure
3-9.
TOXIC WELL DEAD  ∑

TOXIC
79
26
10  115


Sd =
25
164
6  195
 WELL


0
0
0  0
 DEAD
TOXIC WELL DEAD 

 TOXIC 0.687
0.226 0.087 

Pd = 
0.841 0.031 
 WELL 0.128


0
0
1 
 DEAD
Figure 3-9 Summation (Sd) and transition probability (Pd) matrices for the subset of
dogs that died.
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The Nd, Vd and SEd are shown in Figure 3-10. After multiplying the estimated
number of cycles by 7, the estimated residence times and 95% confidence intervals in
days are shown in Figure 3-11.
TOXIC WELL 
TOXIC WELL 





N d = TOXIC
1.54
2.71 
7.65
10.88 Vd = TOXIC




1.51
3.09 
6.17
15.06 
 WELL
 WELL
TOXIC WELL 


SEd = TOXIC
0.94
1.08 
0.60
1.56 
 WELL
Figure 3-10 Estimated mean number of cycles (Nd) an animal resided in each transient
state for the subset of dogs that died. Vd is the variance and SEd is the standard error of
those estimates.




Toxic
Well 
∑


54
76

 130
N d (days) = Toxic

(41-66
(61-91)  (102 − 157)


 149
43
105
 Well

(35 − 51) (84 − 127)  (119 − 178)

Figure 3-11 Estimated mean number of days (95% Confidence interval) an animal
resided in each transient state for the subset of dogs that died.
Weighting these estimates in Figure 3-11 according to the number of dogs
starting the study in each state, gave a weighted survival time of 135 days.
The estimated residence time in each state and the estimated weighted overall
survival time from Monte Carlo simulation of the chain based on Pd are given in Table
3-4. The weighted overall survival time was 121 days (95% CI 114-128).
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Table 3-4 Mean estimated residence times (days) in specified heath states given a
specified starting state in the subset of dogs that died. The weighted mean, based on
the distribution of starting states in the subset, was used to calculate the estimated of
the weighted overall survival time.

Starting
state

Residence in
TOXIC

Residence in
WELL

Conditional
survival

TOXIC
(n=100)

42 days
(35-50)

80 days
(63-97)

123 days
(101-144)

WELL
(n=100)

34
(27-40)

83
(69-97)

117
(97-136)

Weighted
overall
survival
121
(114-128)

Kaplan-Meier estimation of the survival curve for the subset for dogs that died
resulted in a point estimate of median survival time of 53 days (95% confidence
interval 5-171 days) and a mean survival time of 131 days (95% confidence interval
53-209 days).
3.4 Discussion
The discrete-time Markov chain is a popular model used for describing the
progression (Silverstein, et al., 1988, Esik, et al., 1997, Sendi, et al., 1999, Craig and
Sendi, 2001) and evaluating interventions of chronic diseases (de Kruyk, et al., 1998,
Stewart, et al., 1998, Aoki, 2000 #136, Ng, et al., 1999). Chronic diseases can often
be described in terms of distinct health states and the Markov chain is a simple but
powerful model that can describe progression through these states. In addition, the
model is easy to construct and study through matrix manipulation and or simulation
(Beck and Pauker, 1983, Briggs and Sculpher, 1998, Craig and Sendi, 2001). The
appeal of the Markov chain model in application to estimation of survival time and
description of disease progression in veterinary studies was for several reasons.
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Firstly it allowed inclusion of multiple outcomes: death, euthanasia and lost-tofollowup, which obviated the need for right-censoring of observations and avoided the
problem of informative censoring of observations from euthanized animals (Hosgood
and Scholl, 2000). Secondly, it allowed animals to enter the study in any health state
which obviated the need for left-censoring. The state of health on entering a cohort,
which is often related to the stage of disease, is often ignored in veterinary clinical
studies. Thirdly, it allowed description of the progression of disease by means of
transition analysis rather than limiting attention to survival time only.
Data from cases of generalized canine lymphoma were chosen to illustrate this
methodology since this is a common cancer diagnosis that is often treated and access
to adequate records was possible.

In addition, it is a disease that can follow a chronic

course, allowing for transitions between health states over the course of survival.
Also, since it is a commonly encountered and treated canine disease, the results of this
study may have appeal to a wide audience. The study was conducted such that the
results would be meaningful however; no attempt was made to evaluate treatment
protocols although this can be a valuable extension of Markov model methodology.
The transition probability matrix was plausible. The probability of death was
much higher from TOXIC, compared to WELL, as was the probability of euthanasia.
The probability of residing in WELL was much higher given that the previous state
was WELL rather than TOXIC. Interestingly, the probability of lost-to-followup was
higher from TOXIC compared to WELL.
The transition analysis showed the probable progression of the disease. This
information is useful for prognosis and individual decision-making (Silverstein, et al.,
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1988, Briggs and Sculpher, 1998). Based on the relative weight of the varying health
states and outcomes in an owners mind, decision making may be facilitated by
viewing such an analysis, particularly when treatment covariates are included in the
Markov model.
Estimation of residence time in each state, the sum of which is considered
survival time, can be performed using matrix algebra or Monte Carlo model
simulation (Beck and Pauker, 1983, Briggs and Sculpher, 1998, Craig and Sendi,
2001). Either method is relatively easy with access to appropriate software. The
estimates obtained by matrix algebra were again plausible. On average, given that an
animal starts the study WELL, they are likely to spend on average 28 days TOXIC and
127 days WELL, for a total survival estimate of 156 days. Note that this was longer
than the survival estimate for an animal that started the study TOXIC. As expected
(since the same probabilities are used in estimation), the results obtained by Monte
Carlo simulation were similar; on average an animal that started WELL survived 138
days and an animal that started TOXIC survived 105 days.
The advantage of the Monte Carlo simulation is that the more simulations
performed, the smaller the confidence interval of the estimate (Briggs and Sculpher,
1998).

We performed 200 individual simulations although up to 1000 or more

simulations can be used for estimation purposes (Briggs and Sculpher, 1998). Monte
Carlo simulation also allows sensitivity analysis of the model with manipulation of the
probabilities and evaluation of the resultant changes in the progression of the disease
or outcome (Craig and Sendi, 2001). In contrast to matrix algebra estimation, Monte
Carlo simulation is not restricted to the time homogeneous model as probabilities
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could be altered, depending on the time course over which the simulations are made
(Briggs and Sculpher, 1998).
For the purposes of comparison, conventional Kaplan-Meier product limit
estimation was performed, equating euthanasia with death as typical of veterinary
clinical investigations. The authors would note however, that they believe this results
in a biased estimate and hence this comparison is not a validation of the Markov
model results (Hosgood and Scholl, 2000). Despite this concern, it was noted that the
Kaplan-Meier point estimate of mean survival of 201 days was considerably longer
than the Markov estimates of 133 and 119 days and had an extremely wide confidence
interval. An internal validation of the Markov model survival estimate would be the
Markov model survival time estimate from dogs that died due to the target disease. It
is important to realize that this sub-population of dogs may be confounded in some
way with the outcome and that dogs that are euthanized and dogs that die may not
necessarily follow the same distribution of potential survival time. Nevertheless,
estimates obtained from the subpopulation of dogs that died were obtained using
Markov estimates and Kaplan-Meier estimates. The estimates derived from matrix
algebra and Monte Carlo simulations (134 and 121 days respectively) were very
similar to the Markov estimates for the entire population (133 and 119 days
respectively) and to the Kaplan-Meier estimate for the dogs that died (131 days). The
Kaplan-Meier estimate of mean survival was equal to the arithmetic mean of the
survival times since all observations were complete (Lee, 1992b). The Kaplan-Meier
estimate was however considerably less than the estimate for the entire population
(201 days). The similarity of the Markov estimates for the subpopulation of dogs that
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died to the estimates for the entire population is expected since the Markov model
truncates all absorbing states similarly. In contrast, the data that ended in LTF was
right-censored in Kaplan-Meier estimation, which has the effect of increasing the
survival estimates and their confidence intervals. This discrepancy highlights the
relative sensitivity of the Kaplan-Meier estimation methods that we had previously
encountered (Hosgood and Scholl, 2000). In both estimations, the relative proportion
the observations from dogs that died contributed to data used for estimation from the
entire population are the same; 25% (310/1218 observations) for Markov estimation
and 25% (16/64 observations) for Kaplan-Meier estimation.
The Markov model estimates were stable and the variance of such estimates
were less than those obtained by Kaplan-Meier estimation. Kaplan-Meier estimation
has been shown previously to be very sensitive to the methods by which outcomes are
classified and to population size (Hosgood and Scholl, 2000). The precision of the
Markov estimates obtained by matrix algebra will be also affected by sample size
(Silverstein, et al., 1988) with small sample sizes resulting in greater variance. This is
a disadvantage of the Markov methods, especially if the population is stratified and
evaluated separately for the purpose of comparison (Silverstein, et al., 1988). In this
situation, Monte Carlo simulation can be useful since the precision of the estimates
can be increased by increasing the number of individual simulations (Briggs and
Sculpher, 1998).
While we believe the Markov model shows promise for the evaluation of
veterinary clinical studies, there are concerns. The underlying Markov assumption,
that the process is memory-less, must be considered (Norris, 1997). In this study it was
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assumed and deemed plausible that the probability of leaving the states WELL or
TOXIC depended only on the current state they were in and was independent of how
many times they had been in TOXIC or WELL previously. Depending on the disease
under investigation, and the model used, this assumption may not hold but can often
be met by the addition of other health states. For example, if recurrence was being
modeled, it may require states of first recurrence, second recurrence and so on if the
probability of leaving these states was different (Sonnenberg and Beck, 1993, Briggs
and Sculpher, 1998).
An additional concern is that of transitional probability homogeneity across
time. This assumption was tested in this study and considered satisfied. However, as
the data becomes less dense towards the latter cycles, the evaluation is less valid.
Methods utilizing more complex mathematics allow for the utilization of timedependent probabilities (Marshall, 1990, Craig and Sendi, 2001) and require further
study of their application to veterinary clinical studies. In addition, simplification of
the model by applying discrete time intervals requires further investigation. Applying
discrete intervals assumes that the transition occurred at the end of the interval when
in fact it may have occurred anywhere within the interval. The larger the interval, the
more information that is lost and the more inaccurate the estimates of survival are
likely to be (Sonnenberg, 1985, Briggs and Sculpher, 1998, Bauerle, et al., 2000).
Methods such as half-cycle correction can be applied, particularly when large cycles
intervals are being used (Briggs and Sculpher, 1998). Another issue related to
transition intervals is the inconsistency of observations of the animals compared to the
transition cycles. Clinical studies do not often involve clear, discrete intervals of
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evaluation and evaluation of animals are often prompted by changes in status. Animals
not observed for several cycles were assumed to have remained in the previous state
when in fact transitions may have occurred in between these observations. In these
situations, application of a continuous time Markov process may be more appropriate
(Marshall, 1990, Anderson, 1991).
Modeling the progression of canine lymphoma was accomplished using a
Markov chain. In addition, estimates of survival time were obtained. An important
distinction must be made between the interpretations of the results of a Markov model
analysis in comparison to traditional survival analysis. The analysis of a survival
curve provides information best suited to hypothesis testing concerning factors that
influence the survival of subject groups, whether this be treatment or disease
characteristics (Silverstein, et al., 1988, Briggs and Sculpher, 1998). However, it is
the contention of the authors that these results are misleading in veterinary studies
since they are biased by observations from euthanized animals (Hosgood and Scholl,
2000). The Markov analysis, in contrast, provides prognostic data best suited to
facilitate decision making for individual subjects (Silverstein, et al., 1988, Briggs and
Sculpher, 1998). In addition, it provides estimates of survival time that can be
partitioned according to the reason for loss and according to the health state of the
animal, information again which is useful for individual decision making. These
estimates appear reliable.
3.5 Notes
a

EPI 2000, Center Disease Control

b

Matlab, Mathworks Inc.
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c

Markov Chain Add-in for Excel Spreadsheets, Jensen, P.A., Bard, J. Operations
Research Models and Methods, University of Texas.
d

SAS v 8.0, SAS Institute, Cary, NC.
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CHAPTER 4 MARKOV MODEL TO COMPARE PROGRESSION OF
VACCINE-ASSOCIATED SARCOMA WITH DIFFERENT TREATMENT
PROTOCOLS IN A COHORT OF 294 CATS
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4.1 Introduction
Vaccine-associated sarcoma (VAS) is an emerging problem in the pet cat
population (Kass, et al., 1993, Coyne, et al., 1997, Gobar and Kass, 2002) and has
received considerable attention regarding preventative and therapeutic strategies,
including the establishment of an American Veterinary Medical Association directed
task force (Richards, 1997). Results of treatment have been reported (Lester, et al.,
1996, Davidson, et al., 1997, Barber, et al., 2000, Hershey, et al., 2000, Bregazzi et al.,
2001, Cohen, et al., 2001, Kobayashi, et al 2002) and the disease appears to follows a
chronic course regardless of treatment protocol. Clinical studies have focused on
hypothesis testing of treatment protocols by comparing survival time and time to
recurrence of two or more treatment groups (Davidson, et al., 1997, Barber, et al.,
2000, Hershey, et al., 2000, Bregazzi, et al., 2001, Cohen, et al., 2001). The results of
these studies do not clearly describe the course of VAS, or provide unbiased
information useful for individual decision-making.
In the clinical setting, prediction of the disease course, prognosis and the
probability of dying are important to the veterinarian and owner. Markov modeling is
a form of stochastic modeling (one which models random events) used in diverse
fields such as computer science, engineering, mathematics, genetics, agriculture
economics, education and biology (Hillis, et al., 1986, Jain, 1986, Stewart, 1994).
Markov modeling can be used to model progression of disease as a series of probable
transitions through health or disease states. Manipulation of the transition
probabilities through matrix solution or simulation can be used to estimate the
probable duration spent in each state. When the process ends in an absorbing state
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such as death, the summation of these durations can be used to expected survival
(Beck and Pauker, 1983, Silverstein, et al., 1988, Briggs and Sculpher, 1998). Since
Markov modeling predicts the future of the process based on estimates of transition
probabilities, it provides information suitable for individual decision-making
(Silverstein, et al., 1988).
This study established a Markov model to compare the progression of VAS in
a cohort of cats undergoing different treatment protocols. Estimates of transition
probabilities, duration spent in disease states and expected survival were compared
between different treatment protocols.
4.2 Methods
4.2.1

Data

Information retrieved from the medical records of 294 cats diagnosed with
VAS from 1989 to 1994 at the University of California at Davis included treatment,
and the time to recurrence, metastasis, re-treatment, death or euthanasia. Recurrence
was defined as recurrence of the local tumor or presence of metastasis. Each cat’s
disease progression was recorded until the end of the study period at which time the
cat was either alive, had died or had been euthanized. The time of last assessment for
cats that were alive but lost to follow-up was recorded. Cats that died or were
euthanized for reasons other than the disease of interest were right censored and thus
considered alive at the time of record.
4.2.2

Treatment Groups

The treatment protocol used for each cat was noted for the purpose of
comparison. Three treatment protocols were defined. NONE was defined as no
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surgical treatment but included cats that received novel medical treatment such as
corticosteroids, acemannin and other unspecified chemotherapy protocols.
SURGERY (SX) was defined as surgical excision of the sarcoma. SURGERY +
RADIATION (SX+RAD) was defined as surgical excision with at least one radiation
treatment within one month of surgical excision. If a cat received radiation at any
time in its disease course, it was categorized in the SX+RAD treatment group. There
was no standardized radiation protocol for cats in this study. Radiation was delivered
using cobalt 60.
4.2.3

Characteristics of Treatment Groups

Age was considered continuous and found to follow a normal distribution after
failure to reject the null hypothesis of normality at P=0.05 using the Shapiro-Wilk
statistic. The mean+/-SEM age of each treatment group was calculated and compared
using a one-way ANOVA. Post-hoc comparisons using Tukey’s test were made where
there was a significant effect of treatment. Type I error was set a 0.05.
An association between age and outcome was explored using proportional
logistic regression. Age (years) was modeled as a continuous variable against the
outcome Alive, Dead and Euthanasia. The single, proportional odds ratio summarized
the odds of dead versus alive and euthanasia versus dead with incremental increases in
age. This analysis was performed since an association between age and outcome,
particularly euthanasia, may suggest confounding of the transition rates between
disease states by age. If such confounding existed, the assumption of time
homogeneity may not hold. Significant association was considered when the 95%
confidence interval of the proportional odds’ ratio excluded 1.0.
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4.2.4

Markov Model

A 5-state Markov model was constructed that included three transient states -ENTRY, RECURRENCE1 and RECURRENCE2+, and two absorbing states -DEATH and EUTHANASIA (Figure 4-1). ENTRY was the starting state of the
model and corresponded to the initial presence of gross disease at the time of
diagnosis for all cats. Since treatment was then applied, for cats that received no
surgery, ENTRY was characterized by the persistence of disease. For cats that
received surgery and or radiation, ENTRY was characterized by the immediate
condition after initial treatment. This condition could not be assumed to be diseasefree. RECURRENCE1 (RECURR1) was defined as the first documentation of
recurrent gross disease or metastasis. Transition into RECURR1 was only possible for
SX or SX+RAD cats. RECURRENCE2+ (RECURR2+) was defined as the second or
later documentation of recurrent gross disease or metastasis. Transition into
RECURR2+ implied that the cat had been re-treated after the first recurrence.
Transition into DEATH or EUTHANASIA (EUTH) was possible from ENTRY,
RECURR1 or RECURR2+.
Time spent in ENTRY, RECURR1 and RECURR2 implied the cats were alive
however, this time was characterized both by presence and absence of disease of gross
disease. It was impossible from the available data to clearly document disease-free
time. Since the primary focus of the study was estimation of probabilities and times to
termination, the model, as it was defined, could clearly describe these features and
compare expected survival (with or without the presence of gross-disease) between the
different treatment protocols.
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Figure 4-1 A 5 state Markov model used to describe progression of vaccine-associated
sarcoma in a cohort of 294 cats. State ENTRY, RECURRENCE1 and
RECURRENCE2+ are transient states. State DEATH and EUTH (Euthanasia) are
absorbing states. The transition rates between transient states are defined as q, into
absorbing states as u.

4.2.5

Transition Probabilities Matrix

Time homogeneity was assumed. Time homogeneity implies that transition
rates remained constant over the duration of the study, for example, that the transition
between two states was the same for cats in March as it was in September. This was a
plausible assumption since it was unlikely that environmental factors associated with
the time of year would influence the course of the disease. The underlying Markovian
assumption, that the transition from a state is dependent only on the current state and
not where the process has been, was also assumed (Stewart, 1994). Sequential
recurrence states were included to avoid possible violation of the Markovian property
since transition into a recurrence state may be dependent on whether previous
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recurrence had occurred. It is possible that recurrence is more likely if a previous
recurrence had occurred.
A one month cycle was used for the Markov chain The rate of recurrence,
dying or of being euthanized from ENTRY, RECURR1 and RECURR2+ was
calculated as events per animal-months where λi = aij / animal-months ; λi is the rate
of moving from state i to state j and aij is the number of events. The probability
corresponding to the rate was calculated as the exponential transform; p = 1 − e − λit
where λi is the rate and t is the time period for which the probability is estimated, in
this case one month (Beck and Pauker, 1983, Silverstein, et al., 1988, Sonnenberg and
Beck, 1993, Miller and Homan, 1994, Sahai and Khurshid, 1996). Thus, the model
was defined as a 5-state time homogeneous discrete Markov chain (Jensen and Bard,
2002a). The transition probability matrices (P) for each treatment group were
established using these probabilities. The probability of staying in the current transient
state was calculated by subtracting the sum of all probabilities of exit from that state
from one. Hence, the sum of the probabilities of each row of the P matrix equaled one
(Norris, 1997, Meerschaert, 1999).
4.2.6

Estimation of State Durations

Monte Carlo (individual) simulation was used preferentially over matrix
solution for estimation of the duration spent in transient states since it affords smaller
variance estimates. Increasing the number of simulations can reduce the variance of
the point estimates of duration (Silverstein, et al., 1988, Sonnenberg and Beck, 1993,
Briggs and Sculpher, 1998). Five hundred simulations were performed for each
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group. Simulations started in ENTRY and continued until absorption into DEATH or
EUTH. The mean (+/-SEM) cycles (time) spent in each state and the cumulative
number of cycles (time) to absorption (expected survival) was calculated for each
group. A 95% confidence was calculated for each estimate. The duration spent in
transient states and the expected survival for each group were compared using a oneway ANOVA (or t-test where appropriate). Post-hoc comparisons using Tukey’s test
were made where there was a significant effect of treatment. Type I error was set at
0.05.
4.2.7

Transient Analysis

Progression of the model was described by a transient analysis of the P matrix
(Silverstein, et al., 1988). The transient analysis was performed by iterating
p n +1 = p n ⋅ P where p n+1 is the vector of probabilities of being in a specified state at the
next cycle, n+1, p n is the vector of probabilities at the current cycle, and P is the
probability matrix. The initial probability vector p0 included a probability of 1 for
ENTRY and 0’s elsewhere since all cats began in the ENTRY state. The transition
analysis was iterated until the probability of being in any transient state was zero.
4.2.8

Sensitivity Analysis

A one-way sensitivity analysis was performed for each group to examine the
behavior of the model under different conditions (Sendi, et al., 1999). The probability
of staying in the transient states ENTRY, RECURR1 and RECURR2+ was increased
from 0 to 1 in increments of 0.1. These probabilities were adjusted since, in theory,
staying in these states represented a curative procedure, either initially or after
development of recurrence. Adjustment of these probabilities was most applicable to
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the clinical situation. All other probabilities in the matrices remained the same, except
for the co-dependent probabilities in the same row. The co-dependent probabilities
were adjusted proportionally to reflect their original distribution and allow the sum of
the row probabilities to remain equal to one. For each increment in probability, the
adjusted expected survival was estimated using cohort simulation with 10,000
subjects. Cohort simulation illustrates the experience of a hypothetical cohort of
subjects as predicted by the adjusted model (Beck and Pauker, 1983, Sonnenberg and
Beck, 1993, Briggs and Sculpher, 1998, de Kruyk, et al., 1998, Bauerle, et al., 2000).
The entire cohort began in ENTRY. At each cycle of the model, the appropriate
transition probabilities were applied and the distribution of subjects in each state of the
Markov model was adjusted. The analysis continued until there were <10 subjects in
all transient states. The number of subjects in each transient state over the cycles was
summed and divided by the number of original subjects (10,000) to estimate the mean
number of cycles spent in each transient state. The sum of the cycles spent in all
transient states, multiplied by one month, estimated the mean expected survival for
each adjusted probability matrix (Beck and Pauker, 1983, Sonnenberg and Beck, 1993,
Briggs and Sculpher, 1998).
All matrix manipulations were performed using MatLab 6a and Markov Chain
Add-in for Excel Spreadsheetsb. All statistical evaluations were performed using SAS
v 8.0c (PROC LOGISTIC, PROC GLM, PROC UNIVARIATE).
4.3 Results
Fifty-nine cats were categorized in group NONE, 208 cats in SX and 27 cats in
SX+RAD. One hundred cats were alive at the end of the study, 25 died and 169 were
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euthanized. Cats in SX+RAD were significantly older (mean +/-SEM 12.72 +/-3.36
years) than cats in NONE (9.69+/- 0.54 years) and cats in SX (9.49 +/- 0.29 years)
(P=0.05, ANOVA). There was no association between age and outcome (alive, dead,
or euthanasia) (95% CI proportional odds ratio 0.97-1.05)
The estimated rates and corresponding transition probability matrices are given
in Table 4-1 and Figure 4-2, respectively. SX and SX+RAD had similar rates and
probabilities of first recurrence. A comparison of absorption after the first recurrence
was not possible. Absorption after the first recurrence for SX+RAD would appear
infrequent and an estimate was not attained in this group, probably due to the small
sample size. SX and SX+RAD had similar rates and probabilities of two or more
recurrences, however, SX+RAD had a much higher rate of absorption after two or
more recurrences. NONE were more likely to be euthanized while SX and SX+RAD
were likely to die.
The estimated duration in ENTRY was not significantly different between
groups (Table 4-2 and Figure 4-3). The estimated duration in RECURR1 and the
estimated duration in RECURR2+ were significantly shorter for SX than SX+RAD
(P<0.001, t-test; P<0.01, t-test, respectively). The mean expected survival was
significantly shorter for NONE than SX than SX+RAD (P<0.05, ANOVA).
For NONE, simulation resulted in 26.3% absorptions by death and 73.7% by
euthanasia, SX had 67.4% absorptions by death and 32.6% by euthanasia and
SX+RAD had 82.2% absorptions by death and 17.8% euthanasia.
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Table 4-1 Estimated transition rates.

Initial State

Transition rates
(events/animal-months)

NONE

Recurr 1

Recurr2+

Death

Euth

Disease

0

0

0.0717

0.2073

Recurr1

-

0

0

0

Recurr2+

0

-

0

0

SX

Recurr 1

Recurr2+

Death

Euth

Disease

0.1165

0

0.0546

0.0901

Recurr1

-

0.1410

0.0694

0.0073

-

0.0976

0.1141

Recurr2+

SX+RAD

Recurr 1

Recurr2+

Death

Euth

Disease

0.1444

0

0.1385

0

Recurr1

-

0.1301

0

0

Recurr2+

0

-

0.6250

0.3074

ALL

Recurr 1

Recurr2+

Death

Euth

Disease

0.1195

0

0.0638

0.1439

Recurr1

-

0.0639

0.0694

0.2202

Recurr2+

0

-

0.1357

0.1254
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PNONE

ENTRY RECURR1 RECURR2+ DEATH EUTH 

 ENTRY
0.7436
0
0
0.0692 0.1872 

 RECURR1
0
1
0
0
0 
=

0
0
1
0
0 
 RECURR2+
 DEATH
0
0
0
1
0 


0
0
0
0
1 
 EUTH

PSX

ENTRY RECURR1 RECURR2+ DEATH EUTH 

 ENTRY
0.7507
0.1100
0
0.0531 0.0862 

 RECURR1
0
0.1912
0.1315
0.6700 0.0073
=

0
0
0.7992
0.0930 0.1078 
 RECURR2+
 DEATH
0
0
0
1
0 


0
0
0
0
1 
 EUTH

PSX+RAD

ENTRY RECURR1 RECURR2+ DEATH EUTH 

 ENTRY
0.7632
0.1345
0
0.1293
0 

 RECURR1
0
0.8780
0.1220
0
0 
=

0
0
0.2707
0.4647 0.2646 
 RECURR2+
 DEATH
0
0
0
1
0 


0
0
0
0
1 
 EUTH

Figure 4-2 Transition probability matrices (P) for 59 cats that did not receive surgical
treatment (NONE) for vaccine-associated sarcoma, 208 cats that received surgery
alone (SX) and 27 cats undergoing surgery and radiation treatment (SX+RAD).
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Table 4-2 Mean (95% CI) residence times (months) generated by Monte Carlo
simulation of the Markov model starting in ENTRY.

Treatment group

Transition state

Expected survival

Entry

Recurr1

Recurr2+

Entry

3.88
(3.62-4.15)

-

-

SX

Entry

Recurr1

Recurr2+

Entry

4.25
(3.45-4.75)

0.70
(0.57-0.83)

0.37
(0.07-0.66)

SX+RAD

Entry

Recurr1

Recurr2+

Entry

4.00
(3.43-4.57)

5.31
(4.25-6.37)

0.83
(0.68-0.98)

Duration in state (months)

NONE

12
10
8

b

ENTRY
RECURR1
RECURR2+

a

3.88
(3.62-4.15)
5.32
(4.73-5.91)
10.14
(8.92-11.35)

**

*

b

a

a

a

NONE

SX

SX+RAD

6

a

4
2
0

Treatment group
Figure 4-3 Estimated duration spent in transient states and mean expected survival for
each treatment group. Duration across states with the same letter are not significantly
different. SX+RAD** had significantly longer mean expected survival (10.14
months) than SX* (5.32 months) and NONE (3.88 months).
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The transient analysis illustrated the successive probabilities over time of being
in the transient states (Figure 4-4). Note that although the overall expected survival
for SX is longer than NONE, the course of the disease for SX is similar to that of
NONE, except for a small proportion of time likely to be spent in recurrence states. In
contrast, the course of the disease for SX+RAD is prolonged by the increased
probability of transition into recurrence states.
Sensitivity analysis showed predictable behavior of the model and estimation
of mean expected survival for all groups. As the probability of residing in the
transient states increased, there was a corresponding increase in mean expected
survival (Figure 4-5). The mean expected survival remained consistently higher for
SX+RAD than SX and NONE. Interestingly, all groups behaved similarly with
minimal increases in expected survival until the probability of remaining in the
adjusted transient state reach 0.7 or more. For NONE, the sensitivity analysis was
intuitive since the probability of remaining in ENTRY had the only impact on
expected survival. For SX, the slope of the sensitivity curve was steepest for ENTRY,
thus increments in the probability of remaining in ENTRY had the most impact on
expected survival. Increments in the probability of remaining in RECURR2+ had the
least impact on expected survival. For SX+RAD, increments in the probability of
remaining in ENTRY also had the most impact on expected survival while the
probability of remaining in RECURR1 and in RECURR2+ had similar but lesser
effects.

106

Probability of residing in state

NONE
1.0

0.8
EUTH
0.6

0.4

0.2

DEATH
ENTRY

0.0
0

5

10

15

20

25

30

35

40

30

35

40

30

35

40

Probability of residing in state

SX
1.0

0.8

EUTH

0.6

0.4

DEATH

0.2
RECURR1
ENTRY
0.0
0
5

RECURR2+

10

15

20

25

Probability of residing in state

SX+RAD
1.0
EUTH
0.8
DEATH

0.6

0.4

RECURR2+

0.2
ENTRY

RECURR1

0.0
0

5

10

15

20

25

Cycles (months)

Figure 4-4 Transient analysis with probabilities of being in any state at any given
cycle (time) conditional in starting in ENTRY.
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Mean life expectancy
(months)

30

NONE

25
20

ENTRY-ENTRY

15
10
5
0

0
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0

Mean life expectancy
(months)

30

SX

Infinity

25
20

ENTRY-ENTRY

15

REC1-REC1
REC2-REC2

10
5
0

30

Mean life expectancy
(months)

Infinity

0
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0

SX+RAD

Infinity

25
20
15

ENTRY-ENTRY
REC1-REC
REC2-REC2

10
5
0

0
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0

Probability of residing in state

Figure 4-5 Impact of increasing probability of residing in transient states ENTRY,
RECURRENCE1 (REC1) and RECURRENCE2+ (REC2) on mean expected survival
for each treatment group.
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4.4 Discussion
This study allowed an integrated assessment of the progression and prognosis of cats
treated for VAS by surgery alone or with radiation. For this cohort, surgery and
radiation resulted in the longest predicted expected survival with a mean of 10 months.
The analysis clearly shows it was the prolonged time after treatment and recurrences
that these cats experienced contributed to extended expected survival.
Interestingly, the time to first recurrence was not different between surgery or
surgery plus radiation and was also similar to the time to death or euthanasia for cats
not receiving surgery. Cats treated for initial recurrence with surgery alone were
likely, on average, to take less than one month to develop subsequent recurrence(s),
however; repeated surgery did prolong their life over no surgical treatment. There was
considerable mortality associated for cats treated for initial recurrence with surgery
alone. Cats undergoing surgery and radiation were likely to take considerably longer
to develop a second recurrence than cats undergoing surgery alone, on average, nearly
five and a half months. The time between recurrences prolonged the expected survival
for SX+RAD over other treatment protocols.
The estimated expected survival with treatment protocols in this study were
similar to reported median and mean survival estimated by Kaplan-Meier product limit
methods in one study of 45 cats (Davidson, et al., 1997). Davidson reported mean and
median tumor-free interval and survival for cats undergoing a single surgical excision
of 16 months each; mean tumor-free interval and survival for cats undergoing two or
more surgical excisions of 11 and 12.6 months respectively, and mean tumor-free
interval and survival for cats undergoing surgery and radiation (cobalt 60 radiation or
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iridium brachytherapy) of 6.7 and 8.2 months respectively. The estimated mean
expected survival with treatment protocols is the current study are however,
considerably shorter than median survival (no means were given) reported by Cronin,
Bregazzi, Cohen, and Kobayashi, however treatment protocols are clearly different.
Cronin reported on 33 cats that had cobalt 60 radiation treatment with 48 Gy in 16
daily 3.0 Gy fractions followed by surgical excision two to four months after
completion of radiation treatment (Cronin, et al., 1998). Some cats also received
doxorubicin. Cronin reported a median disease-free interval and median survival for
cats undergoing radiation and surgery (and sometimes chemotherapy) of 13.3 and 20
months respectively. Kobayashi used data from Cronin’ study and data from an
additional 59 cats (total of 92 cats) that received the same preoperative cobalt therapy
(Kobayashi et al., 2002). Some cats also received doxorubicin or carboplatin.
Kobayashi reported median time to death, local recurrence or metastasis (whatever
occurred first in each cat) for cats undergoing radiation and surgery (and sometimes
chemotherapy) of 19.4 months. Bregazzi reported the results for 25 cats that had
surgical excision followed by electron beam radiation treatment with approximately
57 Gy delivered in 19 fractions of 6mV photons or 5-12 MeV electrons, depending on
the thickness of the tumor (Bregazzi, et al., 2001). Some cats also received
doxorubicin. Bregazzi reported median survival for seven cats undergoing surgery and
radiation of 20.8 months. The median disease-free interval was not estimable for these
cats. Bregazzi reported median disease-free interval and survival for 18 cats
undergoing surgery, radiation and chemotherapy of 22 and 28 months respectively.
Cohen reported the results for 78 cats that had surgical excision followed by electron
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beam radiation treatment with 13 fractions of 400cGy treated at 4MeV, 6MeV or 8
MeV electrons, depending on the thickness of the tumor (Cohen, et al., 2001). Some
cats also received doxorubicin or cyclosphosphamide. Cohen reported median diseasefree interval and survival for cats undergoing surgery and radiation (and sometimes
chemotherapy) of 13.5 and 24 months respectively.
Since categorization of treatment protocols and groups are not the same for the
current study or these previous studies, direct comparisons are difficult. More
importantly, it must be realized that estimates in the current study are based on
different methodology, which requires different assumptions. Direct comparisons
should be discouraged. Instead, appropriate interpretation and validation of each
estimate should be explored.
Generation and comparison of survival functions by Kaplan-Meier product
limit estimation is useful for hypothesis testing although it does not allow modeling of
regression covariates. Instead, stratification of data on possible covariates is performed
(Lee, 1992b). Kaplan-Meier product limit estimation is based on an underlying
assumption of non-informative censoring (Lee, 1992a). Unfortunately, Kaplan-Meier
estimation is sensitive to classification of observations, which makes comparisons
between studies unreliable (Hosgood and Scholl, 2000). In particular, there is no
ability to accommodate observations from euthanized animals other than equating
them with death (Davidson, et al., 1997, Barber, et al., 2000, Hershey, et al., 2000,
Cohen, et al., 2001). Investigators commonly report median survival times as a
summary measurement of their data (Davidson, et al., 1997, Barber, et al., 2000,
Hershey, et al., 2000, Cohen, et al., 2001, Kobayashi, et al., 2002). The median
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survival time does not convey prognostic or predictive information. The median
survival time is the time at which the survival function transects the 0.5 quartile of the
probability of survival. This is not equal to the arithmetic median and varying
proportions of the cohort may be alive or dead at this point. In some cohorts, a median
may be inestimable if the survival function does not cross this quartile (Lee, 1992a).
The median is substantially affected by the slope of the early part of the survival
function and hence the early experience of the cohort. The median does not reflect the
shape of the survival function, which is better described by the mean. The mean is
equivalent to the area contained under the survival function and is only equal to the
arithmetic mean if all observations are complete (Lee, 1992a). Unfortunately, several
previous investigators of VAS (Cronin, et al., 1998 Bregazzi, et al., 2001, Cohen, et
al., 2001, Kobayashi, et al., 2002) did not report the mean survival times calculated
from the estimated survival functions.
In the clinical setting, veterinarians and owners require information on the
disease course, the prognosis and the probability of the pet dying. This information is
important for individual treatment selection and decision-making. The survival
function cannot easily provide this information and it is the hazard function that
describes the conditional risk of dying (Silverstein, et al., 1988). The hazard rate
describes the conditional probability of dying after time t, given that the subject has
survived to time t. The hazard rate depends on both the survival rate and the rate of
change (slope) of the survival curve (Silverstein, et al., 1988). An often-overlooked
limitation of survival curve analysis results from inappropriately interpreting the
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survival function of a group after a time interval as the probability of future survival
for an individual who has survived to that time period (Silverstein, et al., 1988).
Estimation of expected survival from a Markov model is akin to estimation of
survival from the hazard function since the transition probability (to death) represents
the future probability of death, given the current state (alive at time t), which defines
the hazard rate. Estimation of expected survival from a Markov model should be
thought of as an extrapolated survival under the assumption that the constant transition
probabilities will continue to apply in the future (Silverstein, et al., 1988). The term
expected survival is used in this paper to convey that it is a projected estimate of
survival. Thus, expected survival is an estimate based on the probability of dying
gleaned from the cohort. This is in contrast to the estimate of median survival time
derived from a survival function, which is a summary statistic of the survival function
of the cohort.
While the probability matrix summarizes transition probabilities of the cohort,
the transient analysis allows prediction or prognosis for an individual subject, given
their starting state, current state and cycle (Urakabe, et al., 1975, Silverstein, et al.,
1988, de Kruyk, 1998 #149, Kuo, et al., 1999, Bauerle, et al., 2000, Myers, et al.,
2000). This is useful information for individual decision-making (Urakabe, et al.,
1975, Silverstein, et al., 1988). For example, given an owner elected surgery and
radiation treatment (and their cat started in ENTRY), if their cat is alive (ENTRY)
after the first treatment at 5 months, the probability that it will continue to be alive or
develop recurrence as opposed to dying or requiring euthanasia is 0.5.
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The validity of the estimate of expected survival derived from the Markov
analysis is dependent on many factors. Any time a model is used, assumptions are
made and acceptance of the model and its limitations are required (de Kruyk, et al.,
1998, Sendi, et al., 1999). In this case, assumption of time homogeneity and a
memory-less process are fundamental. For the purpose of this study, these
assumptions were deemed plausible. It is unlikely that environmental conditions
influenced transition probabilities over the course of the study. Violation of timehomogeneity is a problem in chronic human disease since aging and development of
concurrent illnesses have a significant influence on mortality rate (Beck, et al., 1982).
Whether this occurs is veterinary populations is undetermined. Yearly increments in
age were not associated with outcome in the cats of this study and age was considered
unlikely to confound the transition probabilities to absorbing states. There was most
concern that age may be associated with euthanasia but this was not apparent.
Although the mean age of SX+RAD cats was older than the other cats, this does not
imply any association of age and treatment but merely helps to describe the
characteristics of the group. Sequential recurrence states were included since
development of recurrence is probably more likely if previous recurrence had
occurred. In addition, absorption rates may be different from the recurrence states.
The precision of estimates of transition probabilities is inherent to the validity
of the model and subsequent estimates of expected survival. Although the
probabilities used in the Markov model were calculated from a large sample with
many subject-time interval observations, precision may be lost when the incidence rate
of transitions per subject time is used to approximate the probability. The incidence
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rate can give an approximation of the probability when rates are small (Silverstein, et
al., 1988). In this study, the exact probability was calculated from the rate was used to
avoid any imprecision. The SX+RAD group had the smallest number of observations
and estimates may have been imprecise, leading to possible inflation of the expected
survival. Estimates of expected survival are most influenced by imprecision when the
probability estimates are small (Silverstein, et al., 1988). An alternative would have
been to collapse the treatment groups to increase the number of observations as long
as this did not violate the Markovian assumption. However, collapsing groups also
risks loss of information. A reduced treatment model was explored where
observations for surgery for cats in SX+RAD were included in estimation of
probabilities for the SX group. There was no gain in information for the comparison
between NONE and SX, probably since the additional information gained for SX was
small. There was, of course, loss of information for the SX+RAD group. The
behavior of the model described by transient and sensitivity analyses was very similar
to the current investigation. No advantages were seen with use of this model, hence
the results are not reported.
The SX+RAD model did perform as predicted during the sensitivity analysis.
Sensitivity analysis provides a tool for studying the behavior of the model (Sendi, et
al., 1999, Aoki, et al., 2000). While it does not provide any confidence statement about
the results, it may reveal inconsistencies in the model, which reflect violation of
assumptions or other problems such as imprecise estimates or flawed data (Lawless
and Yan, 1993, Cowen, et al., 1994, Sendi, et al., 1999, Aoki, et al., 2000, Jacobs, et
al., 2001). One-way sensitivity analysis was easily computed in this study and no
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major deviances were detected. Manipulation of two or more variables together
becomes complex because a two or more dimensional polyhedron rather than a single
line describes the range of values (Jensen and Bard, 2002b). It must be remembered
however, that one-way sensitivity analysis gives limited estimation of uncertainly
because the results are a function of the entire matrix and not just a single probability
(Sendi, et al., 1999).
Another application of sensitivity analysis is to predict changes in outcome
with manipulation of probabilities in the model. Expected survival increased as the
probability of staying in ENTRY, RECURR1 and RECURR2+ increased. The
probability of staying in these states, in theory, represented a curative treatment. It
was noted however, that expected survival did not increase appreciably until the
probabilities of staying in these states increased above 0.8. Thus, unless treatment
would result in at least an 80% chance of being a curative procedure, it would not
prolong expected survival. This information has importance in decision-making and
also in developing new treatment strategies.
Estimates of state durations and expected survival derived from matrix
solution, Monte Carlo simulation or cohort simulation give similar results if equivalent
transition probabilities and distributions are used, and if a large number of life
histories are generated with the Monte Carlo approach (Briggs and Sculpher, 1998, de
Kruyk, et al., 1998). The variance of these estimates may however vary. Monte Carlo
simulation was used in this study because it has the advantage of generating variances
very easily, which can be reduced by increasing the number of simulations. Monte
Carlo simulation is however, a time-consuming process. Matrix solution is simple and
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gives an exact solution. Matrix solution could have been used in this study since the
stationary probability matrix described the model. However, matrix solution invariably
generates large variance estimates, of the magnitude of the estimated state durations,
which can prohibit comparisons (Silverstein, et al., 1988). Cohort simulation was
used for the sensitivity analysis since it generates an estimate rapidly. However, it is
restrictive since it does not generate a variance estimate and is less suitable when
comparisons between estimates are required (Briggs and Sculpher, 1998).
There is discrepancy among the previous studies on whether radiation in
conjunction with surgery is beneficial. Our results would agree with that of Cohen
(Cohen, et al., 2001) and support beneficial effects of radiation. No attempt was made
in our study to examine adequacy of surgical excision or categorize cats according to
number of procedures (Davidson, et al., 1997). Comparing cats that had one versus
two or more procedures, or adequate versus inadequate resection would appear futile
(Davidson, et al., 1997, Cohen, et al., 2001). Instead, the number of surgical
procedures was incorporated into the model through the sequence of recurrence states.
This has the advantage of viewing these events in context of the complete process.
The transient analysis highlighted how the time to and between recurrences is
principal to the expected survival of treated cats.
Treatment protocols were not applied as part of a randomized clinical trial in
this study or previous studies. Hence, bias is introduced in the number and type of
treatments performed and hypothesis testing of protocols is invalid. All results must be
interpreted in light of this and any statistical testing should be used to enhance the
description of the groups rather than the basis for decisive conclusions. It would be
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intuitive that cats undergoing one procedure would have a better prognosis than those
undergoing two or more (Davidson, et al., 1997, Cohen, et al., 2001). Cats requiring
one procedure are likely to have had easily resectable disease and consequently did not
require multiple procedures to attempt to completely excise the lesion. In contrast, it
is likely that radiation is recommended and applied to cats with non-resectable or
incompletely resected lesions, that is, the worst cases. In addition, it takes a certain
commitment by an owner to elect this treatment protocol (cost, time). In light of this
bias, the benefit of adjunct radiation therapy suggested by this study and Cohen’s,
may be more encouraging since it was possibly selected for cats with the worst
lesions.
Euthanasia represents premature absorption from the process. Euthanasia
represents a complicated informative-censoring situation where the subjects fail due to
a secondary outcome of interest (euthanasia) that causes them to be censored
according to the primary outcome of interest (death) (Lagakos, 1979). Euthanasia also
represents a competing risk (Llorca and Delgado-Rodriguez, 2001). This situation
becomes complicated because the objective for most competing risks is to estimate the
time of failure from a particular cause when other causes of failure are not in effect.
However, in this case, the complete observation of the survival time of interest is an
unachievable event (Lagakos, 1979). In the Markov model, this would require
estimating the transition probability from euthanasia to death which is obviously
impossible.
Markov modeling has the ability to cope with informative censoring. If the
data is dense enough, data that fails to meet the assumption of non-informative
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censoring can be handled by definition of additional absorbing states (Hillis, et al.,
1986, Diggle and Kenward, 1994). The impact euthanasia has on the Markov process
can be visualized in the transient analysis. By including euthanasia as a separate
absorbing state, its probability is acknowledged and the absorption can be noted.
However, since it becomes an identified endpoint, and there is no estimate of the
transition from euthanasia to death, it truncates the estimates of expected survival as
any termination would.
Despite, the inadequacies of a historical treatment cohort, this study clearly
showed that commitment to treatment and retreatment did extend the expected
survival of cats with VAS. Repeated treatment with surgery or surgery with radiation
did extend the expected survival of cats over no surgical treatment.
4.5 Notes
a

MatLab 6, The Mathworks Inc.

b

Markov Chain Add-in for Excel Spreadsheets, Jensen, P.A., Bard, J. Operations
Research Models and Methods, University of Texas.
c

SAS V 8.0, SAS Institute, Cary, NC.
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SUMMARY
Investigators of veterinary clinical studies apply a limited array of statistical
methods and almost exclusively use Kaplan-Meier product limit methods for analysis
of time-event data. Unfortunately, the intent of the analysis or the assumptions
required are often inappropriate for the methods applied. Application of survival
analysis to clinical studies restricts the observation of the disease to two states – alive
or dead (or other outcome), and restricts the analysis to determining the differences
between survival functions for the entire study period.
Investigators in veterinary clinical studies continue to struggle with
classification of observations from animals that are euthanized, as evident by the array
of classification protocols used, ignorance of the problem, and certain comments made
by investigators. The first study showed that Kaplan-Meier product limit estimation is
sensitive to classification of observations and provided unstable estimates of median
and mean survival time, particularly when there was a high frequency of rightcensored observations. Of particular concern was the result of reversed ranking of
point estimates of median survival time by use of different classification protocols
(ones that are currently used by other investigators), which may influence
investigators conclusions and decision-making.
Modeling the progression of canine lymphoma was accomplished using a timehomogenous Markov chain. Estimates of expected survival were obtained and
appeared plausible. Estimates of survival could be partitioned according to the time
spent in different health states, conditional on the starting state of the animal. In
addition, the cause of loss could be identified. This information is useful for
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individual decision-making. The estimates of survival obtained by matrix solution and
Monte Carlo simulation were similar and appeared reliable.
A 5-state Markov model was used to compare progression of vaccineassociated sarcoma in a cohort of 294 cats receiving different treatments. Transition
probabilities were derived from exponential transformation of incidence rates.
Separate P matrices were constructed for each treatments – NONE (no surgery), SX
(surgery) and SX+RAD (surgery and radiation). Estimates of time spent in transient
states and life expectancy (expected survival) were generated by Monte Carlo
simulation for each treatment. SX+RAD prolonged life expectancy significantly
longer than SX than NONE. The time spent in transient states of recurrent disease
contributed to the prolonged life expectancy. Commitment to repeated treatment with
surgery, or with surgery and radiation, is required to prolong the life expectancy of
cats with vaccine-associated sarcoma.
An important distinction must be made between interpretations of Markov
analysis and traditional survival analysis. The analysis of a survival curve provides
information best suited to hypothesis testing concerning factors that influence the
survival of stratified groups, whether this is a treatment or disease characteristic. The
Markov analysis, in contrast, provided prognostic data best suited to facilitate
individual decision-making.
Although Markov modeling has its own set of restrictions and limitations, its
application to veterinary clinical studies has merit and allows an array of analyses.
The work of this dissertation would support further exploration of this methodology
for evaluation of veterinary clinical studies. Acquisition of prospective data with
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random variables would be a useful step. Acquiring quality data with the intent of
Markov analysis is important to continued exploration and validation of Markov
models for veterinary clinical data. More rigorous testing of the time homogeneity
assumption and application of more advanced techniques that include fixed and timedependent covariates would be an obvious next step.
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APPENDIX I DERIVATION OF THE N MATRIX
Briefly, when Q is multiplied by itself, Q x Q = Q2, the product matrix is
composed of the probabilities of the animal being in each transient state after two
cycles (Beck and Pauker, 1983, Brown and Brown, 1990b). When this matrix is
multiplied again by Q, the elements of Q3 represent the probabilities of being in a
specified transient state after three cycles. This process can be repeated indefinitely;
after each cycle the entries in Q will decrease because the Markov model has
absorbing states and eventually all subjects will be absorbed. Thus Qn → 0 as n gets
very large and eventually no subjects are in a transient state. Because the limit of Qn
approaches a zero matrix, the sequence I +Q + Q 2 + Q 3 + ... is bounded and represents
a matrix of life expectancies. The I (identity) matrix is analogous to giving a subject a
one unit incremental utility for starting in a particular transient state. The sum (S) is
itself a matrix of the same dimensions as Q. Thus S = I +Q + Q 2 + Q 3 + ... If the
following manipulations are performed,
S ( I - Q ) = ( I +Q + Q 2 + Q 3 + ...Qn-1 ) ( I - Q )
= ( I +Q + Q 2 + Q 3 + ...Qn-1 ) − ( Q + Q 2 + Q3 + ...Qn )
= ( I - Qn )

Since Qn approaches zero, S ( I −Q ) = I .
Because the inverse of ( I −Q ) , ( I −Q )′ exists, multiplying the equation by the
inverse gives
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S ( I −Q )( I - Q )′ = I ( I - Q )′
∴ S = ( I - Q )′

Thus S, is the sum of the powers of Q, is equal to the inverse of I-Q or N (the
fundamental matrix of a Markov chain). The elements of N are seen as the expected
residence time before absorption given starting the chain in either row of N.
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APPENDIX II DERIVATION OF THE V MATRIX

If survival is considered as a two state Markov chain, and p is the probability
of death, 1-p is the probability of surviving during that cycle. The transition matrix is
1 − p
 0


p
. Since survival is the waiting time for the first occurrence of death, the
1 

number of cycles that a subject survives can follow a geometric distribution, the
simplest waiting time distribution (Casella and Berger, 1990, Hogg and Craig, 1995).
For the geometric distribution,
Prob (surviving X cycles=x; p )=p(1- p )( x-1) where x =1,2,3,4… and
EX =

1
1− p
and VarX = 2 .
p
p

The variance can be rewritten as VarX =

2− p 1
1
1
− 2 = 2 (2 − p ) − 2 .
2
p
p
p
p

Since the expected survival time (time to death) is given by the inverse of the
probability of death, this can be likened to taking the inverse of the Q matrix to
determine the N matrix (Beck and Pauker, 1983). If we let n =

1
, then
p

VarX = n 2 (2 − n −1 ) − n 2 = n (2n − 1) − n 2
For the purpose of calculation of the variance of the N matrix with more than
two states, n is replaced by vectors for each starting state such that V = N( 2N - I) - N 2 .
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